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ABSTRACT 
 Obesity results when energy intake chronically exceeds energy expenditure, driving 
accumulation and malfunctioning of white adipose tissue and increasing risk for comorbidity. 
Brown adipose tissue (BAT) burns energy via adaptive thermogenesis, a process gaining 
therapeutic interest to restore energy balance in obesity. PACAP regulates energy expenditure 
including thermogenesis in BAT, but the neuronal circuits involved are not well known. Thus, 
we aim to develop a tool to safely restore PACAP in the hypothalamic ventromedial nucleus 
(VMN) of PACAP-null mice to assess the VMN’s contribution. We also investigated whether 
PACAP directly regulates BAT function by binding at adipocytes. We discovered PACAP 
receptor expression in BAT and genetic regulation of receptor expression with cold 
acclimation. Acute in vitro studies did not show PACAP-stimulated thermogenesis in BAT. 
Studying adaptive thermogenesis and its hypothalamic regulation will contribute to the field 
of energy metabolism, and the pathophysiology of obesity and type 2 diabetes. 
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virus (Vigene Biosciences) to show efficacy of injection strategies in 
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of the brain) or (b) the ventromedial nucleus of the hypothalamus (1.46 
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to the top of the brain). The third ventricle (V3) and median eminence 
(ME) are included as hypothalamic landmarks. Nuclei were stained with 
DAPI in mounting media and EGFP autofluorescence was imaged on the 
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Fig 2.5 Representative twelve-image (100x mag. each) stitch taken on the FITC 
channel of a coronal-aspect whole brain cryosection from a male 
C57BL/6 mouse 2.5 weeks following a single intracranial injection 
containing 1013vg/kg (viral genomes per kg body mass) of pscAAV9-
SF1-GFP packaged in AAV9 virus (Vigene Biosciences) to show 
anatomical distribution of autofluorescent EGFP expression and evaluate 
injection accuracy. The dentate gyrus (DG), hypothalamus (H), and third 
ventricle (V3) are outlined as anatomical landmarks. The injection was 
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posterior to bregma, 0.39 mm lateral to the midline, 5.7 mm inferior to 
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to evaluate specificity and efficacy of EGFP expression. Image 72 (a) was 
taken from the Allen Mouse Brain Reference Atlas (coronal aspect) and 
included for spatial context then enlarged to show hypothalamic nuclei 
(b), coloured red. The corresponding brain section area (c) from an adult 
male mouse 2.5 weeks following a VMH-targeted injection of scAAV9 
virus containing pscAAV-SF1-GFP plasmid at a concentration of 
1013vg/kg (viral genomes per kg body mass) shows the distribution of 
plasmid-encoded EGFP expression. Hypothalamic anatomical landmarks 
include the dorsomedial nucleus (DMH), ventromedial nucleus (VMH) 
and third ventricle (V3). Nuclei were stained with DAPI in the mounting 
media and EGFP was detected through autofluorescence on the FITC 
channel. Image 24 (d) was taken from Allen Mouse Brain ISH Atlas for 
the nuclear receptor (Nr5a1), aka SF1. This image shows the 
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corresponding area stained with an in situ antisense RNA probe and was 
included to compare the anatomical area of EGFP expression following 
intracranial injection (c) to wild-type SF1 expression in the hypothalamus 
(d). Images (a) and (d) collected from the following URL with free, open 
access permission © Allen Institute. 
© [2004] Allen Institute for Brain Science. Allen Mouse Brain ISH Atlas, 
Coronal. Available from: https://mouse.brain-map.org/search/index. 
 
Fig 2.7 Representative images of DAPI-stained hypothalamic coronal-aspect 
cryosections from male C57BL/6 mice 2.5 weeks following a single 
intracranial injection containing 1013vg/kg (viral genomes per kg body 
mass) of pscAAV9-SF1-GFP packaged in AAV9 virus (Vigene 
Biosciences) to show cellular localization of EGFP expression and cell 
morphology of EGFP-positive cells. EGFP-positive cell bodies and 
indicated solid arrowheads and their EGFP positive projections are 
indicated by open arrowheads. Nuclei were stained with DAPI in 
mounting media and EGFP was detected through autofluorescence on the 
FITC channel. Field of view indicated for each micrograph, which were 
taken at 400x (a,b,c) or 100x magnification (d). 
 
48 
Fig 3.1 Manufacturer protocol for the Agilent Seahorse Mitochondrial Stress Test 
kit to show expected effects of kit reagents on oxygen consumption in 
cultured adipocytes. Image created from data in this Chapter.  
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Fig 3.2 Whole body mass, composition, and post-mortem adipose tissue mass 
measured over 3.5 weeks of cold acclimation (housing at 4°C) in male 
C57BL/6 mice compared to thermoneutral-housed (30°C) control mice. 
Body mass (a), lean mass (b), and total fat mass (c) were measured by 
non-invasive time-domain nuclear magnetic resonance (Bruker minispec 
LF50) (n = 8 for days 0 and 21, n = 4 for days 7 and 14). Sample size 
differs due to technical problems. Adipose depot mass (d) of interscapular 
brown adipose tissue (BAT) subcutaneous inguinal while adipose tissue 
(ingWAT), and visceral gonadal adipose tissue (gWAT) determined by 
dissection measured post-mortem at 3.5 weeks (n = 8). Data are expressed 
as mean ± SD and asterisks denote a significant temperature effect at α = 
0.05 (30°C vs. 4°C). 
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Fig 3.3 Cold acclimation of interscapular brown adipose tissue (iBAT) after 3.5 
weeks of cold acclimation (4°C housing) in male C57BL/6 mice 
compared to thermoneutral-housed (30°C) control mice. Representative 
bright field images (a and b) of Hematoxylin- and Eosin-stained sections 
of dissected iBAT taken at 600x magnification. Histological analysis of 
iBAT from cold-acclimated mice showing lipid area (c) as a percentage 
of the total region of interest (ROI) area and the number of brown 
adipocytes (d) per ROI (n = 4) as determined by nuclei count. Micrograph 
acquisition, and image processing for lipid area quantification were 
performed using Olympus CellSens software, while nuclei counts were 
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performed manually from visual analysis of the images. Relative mRNA 
expression (e) of genes related to iBAT thermogenesis: uncoupling 
protein 1 (UCP1), b3 adrenergic receptor (b3-AR), and hormone-sensitive 
lipase (HSL) (n = 8/group). Expression was normalized to the endogenous 
controls TATA binding protein (TBP) and ribosomal protein (RP)-L19. 
Data are expressed as mean ± SD and asterisks denote a significant 
temperature effect at α = 0.05 (30°C vs. 4°C). 
 
Fig 3.4 Cold acclimation of inguinal white adipose tissue (ingWAT) after 3.5 
weeks of cold acclimation (4°C housing) in male C57BL/6 mice 
compared to thermoneutral-housed (30°C) control mice. Representative 
bright field images (a and b) of Hematoxylin- and Eosin-stained sections 
of dissected ingWAT taken at 600x magnification. Relative mRNA 
expression (c) of genes related to thermogenesis in ingWAT: uncoupling 
protein 1 (UCP1), homeobox protein (HOX)-C9, and hormone-sensitive 
lipase HSL (n = 8/group). Expression was normalized to endogenous 
controls: ribosomal 18S rRNA, beta-actin, and glyceraldehyde-3 
phosphate dehydrogenase. All data are expressed as mean ± SD unless not 
detected (n.d.) and asterisks denote a significant temperature effect at α = 
0.05 (30°C vs. 4°C). 
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Fig 3.5 Cold acclimation of gonadal white adipose tissue (gWAT) after 3.5 weeks 
of cold acclimation (4°C housing) in male C57BL/6 mice compared to 
thermoneutral-housed (30°C) control mice. Representative bright field 
images (a and b) of Hematoxylin- and Eosin-stained sections of dissected 
gWAT were taken at 600x magnification. Relative mRNA expression (c) 
of genes related to thermogenesis: uncoupling protein 1 (UCP1), 
homeobox protein (HOX)-C9, and hormone-sensitive lipase (HSL) (n = 
8/group). For UCP1, n = 6 in the cold treatment group as two mice with 
extremely high relative fold mRNA expression (24 and 1450) were 
excluded. Expression was normalized to the endogenous controls 
(ribosomal 18S rRNA, beta-actin and glyceraldehyde-3 phosphate 
dehydrogenase. All data are expressed as mean ± SD unless not detected 
(n.d.) and asterisks denote a significant temperature effect at α = 0.05 
(30°C vs. 4°C). 
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Fig 3.6 Expression of genes related to pituitary adenylate cyclase-activating 
polypeptide (PACAP) signaling in cold-acclimated interscapular brown 
adipose tissue (iBAT) (a) and cultured primary brown adipocytes (b), 
including vasoactive intestinal peptide (VIP), PACAP receptor 1 
(PAC1R), and VIP/PACAP receptor 1 and 2 (VPAC1/2). iBAT (a) was 
dissected from male C57BL/6 mice acclimated to cold (4°C) for 3.5 
weeks (n = 8/group) to mice housed at thermoneutrality (30°C). Primary 
brown adipocytes (b) were collected from iBAT of non-acclimated (24°C) 
mice and adipocytes were pooled from 4 mice for each well (n = 3/group). 
Expression was normalized to the endogenous controls TATA binding 
protein, and ribosomal protein L-19. All data are expressed as mean ± SD 
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unless not detected (n.d.) and asterisks denote a significant temperature 
effect at α = 0.05 (30°C vs. 4°C) for iBAT (a), and significant 
differentiation effect for primary cultures (b).  
 
Fig 3.7 Expression of genes related to pituitary adenylate cyclase-activating 
polypeptide (PACAP) signaling in cold-acclimated inguinal white 
adipose tissue (ingWAT) (a) and cultured primary white adipocytes (b) 
from ingWAT, including vasoactive intestinal peptide (VIP), PACAP 
receptor 1 (PAC1R), and VIP/PACAP receptor 1 and 2 (VPAC1/2). 
ingWAT (a) was dissected from male C57BL/6 mice acclimated to cold 
(4°C) for 3.5 weeks (n = 8/group) to mice housed at thermoneutrality 
(30°C). VPAC2 was detected (at levels nearing the limit of detection (Ct 
> 35)) only in some ingWAT samples from both treatment groups and 
was therefore considered to be not detected. Primary white adipocytes (b) 
were collected from ingWAT of non-acclimated (24°C) mice and 
adipocytes were pooled from 4 mice for each well (n = 3/group). 
Expression was normalized to endogenous controls: ribosomal 18S 
rRNA, beta-actin, and glyceraldehyde-3 phosphate dehydrogenase. All 
data are expressed as mean ± SD unless not detected (n.d.) and asterisks 
denote a significant temperature effect at α = 0.05 (30°C vs. 4°C) for 
acclimated ingWAT (a), and significant differentiation effect for primary 
cultures (b). 
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Fig 3.8 Expression of genes related to pituitary adenylate cyclase-activating 
polypeptide (PACAP) signaling in cold-acclimated gonadal white adipose 
tissue (gWAT) (a) and cultured primary white adipocytes (b) from 
ingWAT, including vasoactive intestinal peptide (VIP), PACAP receptor 
1 (PAC1R), and VIP/PACAP receptor 1 and 2 (VPAC1/2). gWAT (a) was 
dissected from male C57BL/6 mice acclimated to cold (4°C) for 3.5 
weeks (n = 8/group) to mice housed at thermoneutrality (30°C). VPAC2 
was detected (at levels nearing the limit of detection (Ct > 35)) only in 
some ingWAT samples from both treatment groups and was therefore 
considered to be not detected. Primary white adipocytes (b) were collected 
from gWAT of non-acclimated (24°C) mice and adipocytes were pooled 
from 4 mice for each well (n = 3/group). Expression was normalized to 
endogenous controls: ribosomal 18S rRNA, beta-actin, and 
glyceraldehyde-3 phosphate dehydrogenase. All data are expressed as 
mean ± SD unless not detected (n.d.) and asterisks denote a significant 
temperature effect at α = 0.05 (30°C vs. 4°C) for acclimated gWAT (a), 
and significant differentiation effect for primary cultures (b). 
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Fig 3.9 Lipolysis in primary brown adipocyte cultures following 2-hour 
stimulation of pituitary adenylate cyclase-activating polypeptide 
(PACAP) receptors. Free fatty acid (a) and glycerol (b) release were 
measured in media of differentiated primary cultures from interscapular 
brown adipose tissue of male C57BL/6 mice (n = 2 wells/treatment). 
Patterns of receptor agonism (+) were achieved using CL316,243 to 
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stimulate b3 adrenergic receptor (b3-AR) as a positive control, pituitary 
adenylate cyclase-activating polypeptide (PACAP) for non-specific 
simultaneous stimulation of VPAC1, VPAC2, and PAC1R, Maxadilan for 
PAC1R-specific activation, and M65 (PAC1R-specific antagonist) plus 
PACAP to stimulate only VPAC1 and 2 but not PAC1R. Data are 
expressed as mean ± SD and asterisks denote a significant effect of 
treatment at α = 0.05 (stimulated vs. saline vehicle control). 
 
Fig 3.10 Lipolysis in primary brown adipocyte cultures following 2-hour 
stimulation of pituitary adenylate cyclase-activating polypeptide 
(PACAP) receptors in combination with b3 adrenergic receptor (b3-AR). 
Free fatty acid (a) and glycerol (b) release were measured in media of 
differentiated primary cultures from interscapular brown adipose tissue of 
male C57BL/6 mice (n = 2 wells/treatment). Patterns of receptor agonism 
(+) were achieved using CL316,243 to stimulate b3 adrenergic receptor 
(b3-AR), pituitary adenylate cyclase-activating polypeptide (PACAP) for 
non-specific simultaneous stimulation of VPAC1, VPAC2, and PAC1R, 
Maxadilan for PAC1R-specific activation, and M65 (PAC1R-specific 
antagonist) plus PACAP to stimulate VPAC1 and 2 but not PAC1R. Data 
are expressed as mean ± SD and asterisks denote a significant effect of 
treatment at α = 0.05 (stimulated vs. saline vehicle control). 
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Fig 3.11 Lipolysis in primary white adipocyte cultures following 2-hour 
stimulation of pituitary adenylate cyclase-activating polypeptide 
(PACAP) receptors. Free fatty acid (a) and glycerol (b) release were 
measured in media of differentiated primary cultures from inguinal white 
adipose tissue of male C57BL/6 mice (n = 2 wells/treatment). Patterns of 
receptor agonism (+) were achieved using CL316,243 to stimulate b3 
adrenergic receptor (b3-AR) as a positive control, pituitary adenylate 
cyclase-activating polypeptide (PACAP) for non-specific simultaneous 
stimulation of VPAC1, VPAC2, and PAC1R, Maxadilan for PAC1R-
specific activation, and M65 (PAC1R-specific antagonist) plus PACAP 
to stimulate only VPAC1 and 2 but not PAC1R. Data are expressed as 
mean ± SD and asterisks denote a significant effect of treatment at α = 
0.05 (stimulated vs. saline vehicle control). 
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Fig 3.12 Lipolysis in white adipocyte cultures following 2-hour stimulation of 
pituitary adenylate cyclase-activating polypeptide (PACAP) receptors in 
combination with b3 adrenergic receptors (b3-ARs). Free fatty acid (a) and 
glycerol (b) release were measured in media of differentiated primary 
cultures from inguinal white adipose tissue of male C57BL/6 mice (n = 2 
wells/treatment). Patterns of receptor agonism (+) were achieved using 
CL316,243 to stimulate b3 adrenergic receptor (b3-AR), pituitary 
adenylate cyclase-activating polypeptide (PACAP) for non-specific 
simultaneous stimulation of VPAC1, VPAC2, and PAC1R, Maxadilan for 
PAC1R-specific activation, and M65 (PAC1R-specific antagonist) plus 
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PACAP to stimulate VPAC1 and 2 but not PAC1R. Data are expressed as 
mean ± SD. and asterisks denote a significant effect of treatment at α = 
0.05 (stimulated vs. saline vehicle control). 
 
Fig 3.13 Activation of thermogenesis in primary brown adipocyte cultures 
following acute stimulation of pituitary adenylate cyclase-activating 
polypeptide (PACAP) receptors alone or in combination with b3 
adrenergic receptor (b3-AR). Oxygen consumption rate was measured in 
media of primary cultures of adipocytes from interscapular brown adipose 
tissue from male C57BL/6 mice (n = 7 wells per treatment). 
Mitochondrial respiration was brought to a minimum using Oligomycin, 
receptors were selectively stimulated, and then the difference (D) in 
oxygen consumption calculated. Patterns receptor agonism (+) were 
achieved using CL316,243 to stimulate b3 adrenergic receptor (b3-AR), 
pituitary adenylate cyclase-activating polypeptide (PACAP) for non-
specific simultaneous stimulation of VPAC1, VPAC2, and PAC1R, and 
Maxadilan for PAC1R-specific activation. Data are expressed as mean ± 
SD and asterisks (*) denote a significant effect (α = 0.05) of treatment 
compared to vehicle (-) control, while daggers (†) denote a significant 
effect of treatment compared to b3-AR stimulated (+) control. 
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Fig 3.14 Oxygen consumption profile of differentiated primary brown adipocytes 
of interscapular origin (a) and differentiated primary white adipocytes of 
inguinal origin (b) from C57BL/6 mice (n = 7/treatment) during the 
Mitochondrial Stress Test Kit assay (Agilent, Santa Clara, CA, USA). 
During the Agonist stage, either saline vehicle (black dots) or CL316,243, 
a specific β3-AR agonist (gray boxes) was added. Data are expressed as 
mean ± SD and asterisks denote a significant effect of treatment at α = 
0.05 (stimulated vs. PBS vehicle control). 
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Fig 3.15 Activation of thermogenesis in primary white adipocyte cultures 
following acute stimulation of pituitary adenylate cyclase-activating 
polypeptide (PACAP) receptors alone or in combination with b3 
adrenergic receptor (b3-AR). Oxygen consumption rate was measured in 
media of primary cultures of adipocytes from inguinal white adipose 
tissue from male C57BL/6 mice (n = 7 wells per treatment). 
Mitochondrial respiration was brought to a minimum using Oligomycin, 
receptors were selectively stimulated, and then the difference (D) in 
oxygen consumption calculated. Patterns receptor agonism (+) were 
achieved using CL316,243 to stimulate b3 adrenergic receptor (b3-AR), 
pituitary adenylate cyclase-activating polypeptide (PACAP) for non-
specific simultaneous stimulation of VPAC1, VPAC2, and PAC1R, and 
Maxadilan for PAC1R-specific activation. Data are expressed as mean ± 
SD and asterisks (*) denote a significant effect (α = 0.05) of treatment 
compared to vehicle (-) control, while daggers (†) denote a significant 
effect of treatment compared to b3-AR stimulated (+) control. 
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Fig 3.16 Oxygen consumption profile of differentiated primary brown adipocytes 
of interscapular origin (a) and differentiated primary white adipocytes of 
inguinal origin (b) from C57BL/6 mice (n = 7/treatment) during the 
Mitochondrial Stress Test Kit assay (Agilent, Santa Clara, CA, USA). 
During the Agonist stage, either saline vehicle (black dots) or CL316,243, 
a specific β3-AR agonist (gray boxes) was added. Data are expressed as 
mean ± SD and asterisks denote a significant effect of treatment at α = 
0.05 (stimulated vs. PBS vehicle control). 
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Chapter One: Introduction to Energy Regulation and Obesity 
 
  
 2 
1.1 THE OBESITY EPIDEMIC: CAUSES AND COMORBIDITY 
 Prevalence of overweight and obesity have been increasing at an alarming rate in 
developed and developing countries in the last four decades1-3. Body mass index (BMI) is the 
most commonly used metric for assessing overweight (25-29.9 kg/m2) and obesity (³ 30 kg/m2) 
and is calculated by an individual’s mass divided by the square of their height. While this 
metric has received criticism for its inability to account for lean mass and metabolic health at 
the individual level, BMI data are ubiquitous and useful for understanding population-level 
trends. In the years 1980-2013, the worldwide prevalence of obesity in adults increased by a 
total of 8%, and in 2013, almost 25% of children in the world were overweight or obese4. The 
rise of obesity has driven a concomitant increase in the prevalence of non-communicable 
diseases such as cardiovascular disease, certain cancers, and type 2 diabetes (T2D). There is a 
growing catalogue of such diseases that can arise as a result of the metabolic consequences of 
obesity, compounding patient suffering and the health care burden. In 2008 alone, obesity-
related health care costs to the US and Canada mounted to an estimated $153 billion1,5. 
Therefore, body mass-related disease is now being recognized as an epidemic6-8. Obesity is 
neither confined to rich countries nor wealthy people. In fact, economically and socially 
disadvantaged groups are at greater risk for the development of obestiy1,9 because low-quality, 
high-calorie diets are cheaper and more accessible than fresh, unprocessed food10. From 2006-
2013, the incidence of overweight in developed countries decreased slightly, but with over 
40% of adults already overweight in many countries, solutions are desperately needed4. 
 The obesity epidemic coincides with a number of negative societal transitions, 
including sedentary lifestyle, increased consumption of processed foods, and urbanization9. In 
Canada, these factors coalesce to form environments that are conducive to a positive energy 
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balance, as reflected by the startling prevalence of obesity. Some First Nations in Canada are 
disproportionately affected by obesity and T2D due to genetic determinants and colonialism-
driven destruction of their traditional diets11 and way of life. This case illustrates how 
disadvantaged groups bear a disproportionate proportion of the burden of obesity-related 
disease. In 2006, an estimated $6 billion was spent by the Canadian health care system in 
treating obesity and its comorbidities, such as hypertension, T2D, and coronary heart disease1. 
 Despite stigmatization that overweight and obese individuals face, many of the 
socioeconomic and biological causes of obesity are beyond individual control or awareness. A 
new study shows evidence that processed food, while it contains more calories per gram, may 
also drive excessive food consumption independent of calorie-seeking behaviour12. This study 
matched calories, macronutrients, sugar, sodium, and fiber between ultra-processed and 
unprocessed meals. They found that participants voluntarily ate more and gained more weight 
when exposed to the ultra-processed diet despite the fact that it did not contain more fats, sugar, 
or calories, which are often hypothesized to be the motivators of excessive eating habits12. This 
shows that there are still unknown mechanisms that contribute to excessive eating, and that 
further work is needed to fully understand the regulation of energy balance. 
 The built environment is another factor that is not under individual control and has 
driven a societal shift to a less active approach to completing activities of daily living. 
Roadways are not often designed to protect active commuters, thereby prohibiting bicyclist 
and pedestrian use7. Increased sedentary behaviour, described as any waking activity 
performed in a sitting or reclined position, correlates to poor weight status in children13. Poorly 
planned urban development combined with automated/digitized personal and professional 
environments have led to increased sedentary behaviour in both adults and children7,9. 
Increased availability of TVs and their incorporation into almost all types of rooms in the 
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household, including bedrooms, has likely contributed to childhood obesity since screen time 
accounts for one-third of sedentary behaviour in children aged 9 to 11 years old13. Taken 
together, poor eating habits and increased sedentary behaviour are the key environmental 
influences driving the obesity epidemic.  
 There are also biological influences that facilitate obesity in addition to and in concert 
with environmental drivers. Obesity has been the target of significant stigma due to a lack of 
understanding of its etiology. This is derived from the false assertion that low physical activity 
and high calorie consumption are the only contributors to the progression of obesity. However, 
there exists a known pathophysiology of obesity including molecular pathways that become 
disturbed and lead to weight gain, dispelling the notion that simple laziness is the culprit. 
Furthermore, the impact of environmental influences differs between individuals. Not all 
sedentary people who consume a high-calorie diet will develop obesity, and not all people with 
obesity will develop metabolic consequences, showing that the pathology of the disease cannot 
be explained by lifestyle factors alone or by a specific amount of adipose tissue accumulation14. 
A number of hormones regulate physical activity and feeding behaviour in times of caloric 
deficiency to maintain energy homeostasis. These behaviors are subject to reinforcement by 
similar circuitry as those that contribute to drug addiction15 and can even override or bypass 
regulators of satiety in the central nervous system (CNS)16. Many neuronal and chemical 
satiety signals originate from the gastrointestinal tract, including cholecystokinin (CCK) and 
ghrelin17. CCK increases satiety and ghrelin opposes it by decreasing perceived fullness and 
increasing normal meal size. Many such processes of energy balance are regulated by both 
positive and negative signals to ensure control within a homeostatic range. The receptivity of 
the CNS to such signals is highly modulated by other organs via endocrine or neurological 
means and thus homeostasis is ensured through a multi-faceted, multi-organ approach. 
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 Adipose tissue, for example, is an important regulator of satiety signal sensitivity in the 
hypothalamus and hindbrain. Leptin, a hormone produced and released from adipose tissue, 
circulates at levels proportional to adipose tissue mass and acts to reduce meal sizes and 
increase satiety signaling in the hindbrain and hypothalamus18 when sufficient energy stores 
exist. However, pathologically high circulating levels of leptin seen in obesity cause leptin 
resistance in the brain and other tissues19-21 through negative feedback mechanisms that 
decrease the expression22 and sensitivity23 of the leptin receptor. In this case, control of energy 
balance is lost, further perpetuating obesity. Understanding these physiological regulators of 
energy metabolism has identified the complex biological regulation of body weight that opens 
up a plethora of potential molecular targets that could contribute to therapeutics for obesity. 
Adipose tissue has thus received much more attention in recent years for its ability to affect 
energy regulating processes in the whole body. 
 
1.2 ADIPOSE BIOLOGY IN METABOLIC DISEASE  
 Historically, white adipose tissue (WAT) has been known for its ability to sequester 
energy in the form of lipid in times of caloric intake and release lipids in times of fasting for 
energy production. This function arose as a consequence of fundamental mammalian biology: 
tissues require energy constantly, but meals are sporadic24. WAT bridges this discrepancy 
between energy supply and demand in its role as the primary organ for energy storage. White 
adipocytes are highly specialized for storing triglycerides in a large cytoplasmic lipid droplet. 
In most other tissues, cellular accumulation of lipid is correlated with processes such as 
inflammation25 and fibrosis26. While some non-adipose tissues can safely store energy in the 
form of glycogen, it is not an efficient storage molecule and provides only a fraction of total 
body energy stores with most energy being stored as lipid in WAT. In humans, glycogen can 
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only provide enough energy to fuel the body for approximately 2-3 hours of intense physical 
activity27, while lipid, accounting for 70% of stored energy, can sustain the body through days 
or weeks28,29. Adipose tissue responds to fluctuating nutrient availability by storage through 
lipogenesis or utilization through lipolysis and lipid oxidation24. Thus, the lipid droplets of 
adipocytes are in constant flux30,31 to maintain high intracellular rates of processes driving 
anabolism and catabolism of lipids. As such, WAT is a dynamic organ that regulates energy 
homeostasis through modulation of metabolic pathways involved in lipid cycling. 
 In the fed state, insulin action and decreased sympathetic stimulation at the adipocyte 
cause a decrease in lipolysis and promote pathways involved in the import, packaging, and 
storage of energy32. The vast majority of lipid is stored as triglyceride in WAT. This critically 
important storage molecule is composed of one glycerol backbone with three fatty acids 
esterified to it. The free fatty acids (FFAs) used to form triglycerides in the WAT come 
primarily from the diet, but they can also be synthesized in the cytoplasm by the repeated 
addition of two-carbon subunits from acetyl-Coenzyme A (acetyl-CoA). The formation of new 
lipids from acetyl-CoA is called de novo lipogenesis and occurs mainly in the liver but is 
stimulated in adipocytes by insulin33. Glucose taken up by adipocytes in response to insulin 
action can also be converted to lipids for storage24. The process of glycolysis breaks glucose 
down into two-carbon units attached to CoA, forming acetyl-CoA that can be utilized in 
lipogenesis. Adipose tissue is therefore a bridge between carbohydrate and lipid metabolism, 
providing an important glucose sink to attenuate blood hyperglycemia. 
 To provide energy during fasting and sustained moderate exercise, stored lipids must 
be made accessible to the peripheral organs including cardiac and skeletal muscle29. Adipose 
tissue accomplishes this via lipolysis, the process of breaking triglycerides down again for 
oxidation or export to the circulatory system. Both glycerol and free fatty acids released from 
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WAT are potential energy sources that can be utilized through the glycolysis pathway and β-
oxidation, respectively. The process is started by the CNS sensing low blood glucose and/or 
free fatty aid. Sympathetic nerves to adipose tissue increase their activity, and depolarization 
releases norepinephrine at the SNS-adipocyte synapse. Beta-3 adrenergic receptors (β3-ARs), 
one type of G-coupled protein receptors (GPCRs) expressed on adipocytes, bind 
norepinephrine and become activated30. Stimulatory G proteins (Gs) associated with the β3-
ARs exchange guanosine diphosphate (GDP) for GTP and dissociate from the receptor to 
activate the enzyme adenylyl cyclase. Increased adenylyl cyclase enzymatic activity results in 
rising cytosolic levels of the secondary messenger cyclic adenosine monophosphate (cAMP). 
High cytosolic concentration of cAMP releases the autoinhibition of c-AMP dependent protein 
kinase A (PKA), which in turn phosphorylates hormone-sensitive lipase (HSL) in an activating 
manner30. HSL translocates to the interior of the cytoplasmic lipid droplet and performs 
hydrolysis of triglycerides32. The resulting FFAs and glycerol can then be exported to the 
plasma for uptake in energetically demanding tissues such as muscle and liver. 
 The current understanding of adipose biology has moved beyond the classical view that 
adipose tissues are semi-inert storage depots. In addition to controlling whole-organism energy 
status through carbohydrate and lipid metabolism, adipose tissue secretes endocrine factors to 
modulate energy homeostasis in other metabolic organs34-39. The identification of cytokines 
secreted by adipose tissue such as tumor necrosis factor alpha (TNFa)40 and leptin41 has 
sparked interest in adipose tissue’s endocrine role in the last 25 years. This work has led to the 
discovery of a new class of adipose-derived signaling molecules termed adipokines, revealing 
an important role for adipose tissue in communicating the whole-body energy status and 
regulating energy intake and expenditure by secreting endocrine factors34. 
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 Friedman and colleagues (1994)41 were the first to discover an adipose tissue derived 
hormone, leptin, promoting the expansion of research surrounding adipose derived endocrine 
regulation of energy balance. As discussed above, leptin decreases appetite and is a modulator 
of both acute and long-term energy status. During fasting in lean individuals, levels of leptin 
decrease, and food intake is promoted. During times of energy excess, leptin is released from 
adipocytes in proportion to the total adipose tissue mass and travels through the bloodstream 
to bind leptin receptors on neurons of the hypothalamus, where it signals satiety and reduces 
appetite42. In obese individuals, circulating leptin levels are high but tissues including adipose, 
hypothalamus, liver, and others become resistant to its effects. For example, levels of soluble 
leptin receptor are decreased in obesity, which may contribute to a state of leptin resistance20,43. 
Reduced leptin sensitivity may have evolved as an adaptation to allow accumulation of energy 
stores and thus more stable energy supply. This adaptation would be particularly important in 
times where excess energy stores are required for survival, such as pregancy44 or hibernation45. 
In obesity, reduced leptin action at target tissues drives further expansion of the WAT through 
increased feeding that further contributes to the level of obesity and to the development of 
metabolic consequences of obesity. 
 While it is true that there are metabolically healthy obese individuals46, a finding that 
can be replicated in genetically modified rodent models of healthy obesity47, there is a well-
characterized association of obesity with a number of life-threatening comorbidities that can 
develop as a result of metabolic syndrome6,42,48. The risk of cardiovascular disease is greatly 
increased in obese individuals, including stroke, heart attack, hypertension, and coronary artery 
disease8. Obesity drives insulin resistance6 and is thus a primary risk factor in the development 
of T2D. Other comorbidities include osteoarthritis, respiratory illness, and some forms of 
cancer9. It should be noted that while comprehensive assessments of obesity-associated costs 
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to Canadian health care resources are rare, worldwide analyses show that Canada has both a 
comparatively high prevalence and overall cost of obesity1-3. Thus, developing 
pharmacological therapeutics aimed at reducing overweight and obesity has been identified as 
a promising approach to reduce health care costs and patient suffering in Canada, in 
combination with lifestyle modification. 
 Normal adipose tissue function is required for the maintenance of metabolic 
homeostasis and impairments in adipose tissue function contribute to the development of 
obesity and drive the majority of comorbidities associated with this disease. Adipose tissue has 
thus been identified as a key promising therapeutic target and the biology of this tissue must 
be explored in greater depth to help reduce the prevalence of obesity. To better characterize 
the participation of adipose tissue in whole-animal metabolism, a mouse model lacking adipose 
tissue was developed49. Adipose tissue development relies heavily on the transcription factors, 
Jun and CAAAT enhancer binding protein (C/EBP) for proliferation and differentiation of 
precursor cells into mature adipocytes, respectively50. Thus, the formation of adipose tissue is 
ablated in transgenic mice with adipose tissue-specific knockout of these transcription 
factors49. The absence of adipose tissue in these mice leads to severe metabolic dysfunction, 
displaying hyperphagia, polyuria, reproductive failure, fatty liver, uncontrolled (50-400 fold 
increase) insulin secretion leading to diabetes49 and premature death. This study shows that 
normal adipose tissue functioning is essential to maintenance of homeostasis. 
 Adipose tissue is a complex organ, and many facets of adipocyte biology become 
perturbed in obesity, such as endocrine function, glucose uptake, and lipid metabolism. In 
obesity, adipose tissues can become over-capacity and therefore unable to take up lipids from 
the blood or manage internal lipids properly. This dysregulated lipid metabolism and resulting 
pro-inflammatory cytokine secretion elevate the inflammatory state in multiple other 
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tissues51,52. Thus, controlling circulating lipids through modulation of lipolysis has long been 
a target for anti-obesity drugs53 due to its potential to remove stored lipid from WAT or, 
conversely, prevent their excretion into the blood. Circulating FFAs directly reduce insulin 
receptor sensitivity and exacerbate symptoms of diabetes54. 
 Despite the critical role adipose tissue plays in the maintenance of metabolic health, the 
increase in obesity and obesity-induced comorbidities have resulted in adipose tissue being 
typically viewed negatively by society, with less attention being given to the positive effects 
of this tissue on metabolism. The adipose tissue is linked to the regulation of glucose 
metabolism, lipid metabolism, feeding behaviour, and inflammation in other tissues through 
the secretion of adipokines. Adiponectin is an example of an adipokine that has widespread 
beneficial effects on many organs and highlights the important role of adipose tissue in 
maintaining metabolic health (Figure 1.1). Adiponectin receptors are expressed in a variety of 
tissues and their transcription appears to be regulated in response to feeding55, perhaps by 
insulin55,56. Autocrine actions of adiponectin include increased glucose uptake, adipogenesis, 
and lipid import in the adipose tissue57. Together, these function to allow the adipose tissue to 
expand while remaining metabolically healthy. Endocrine functions of adiponectin include 
increased insulin sensitivity and secretion, increased FA oxidation, reduced lipogenesis, and 
maintenance of viability in myocytes35, β-cells58, and hepatocytes57. Unlike most other 
adipokines, adiponectin’s expression is very low in obesity. Since adiponectin is an important 
anti-fibrosis and anti-inflammatory cytokine, some facets of metabolic syndrome can be 
explained by its attenuated expression seen in obese individuals. Thus, adiponectin is an 
example of an adipokine that aids in opposing many of the pathophysiological processes seen 
in metabolic syndrome and the development of T2D, but it is only one of many hormones that 
are secreted by the adipose tissue. 
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Figure 1.1. Metabolic, anti-inflammatory, and anti-apoptotic effects of adiponectin on multiple organ systems and 
cell types to highlight the importance of adipose tissue-derived endocrine/autocrine factors (adipokines) in whole 
body function. Modified from Ye, et al. (2013)59 under Creative Commons license. 
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 Hundreds of other peptides are secreted from the adipose tissue36,39 and may also prove 
promising targets as anti-diabetic agents. The identification of adipose-derived endocrine 
factors has greatly increased our understanding of how adipose tissue influences whole body 
metabolism and pathological mechanisms that can lead to metabolic syndrome when adipokine 
levels change in obesity. This provides promising targets for pharmacological therapies and 
has resulted in better treatment of obesity and T2D. For example, leptin therapy in obese 
individuals has been shown to decrease voluntary food intake and increase voluntary exercise, 
thus reducing fat mass and leading to a significant decrease in BMI21. In general, it is accepted 
that a negative energy balance is desirable for obese and overweight individuals, though other 
metrics have also been used as indicators of efficacy in interventions60,61. A negative energy 
balance leads to decreased mass of the body’s main energy stores, the WAT. This ameliorates 
over-capacity, malfunctioning WAT, thus improving the metabolic profile. The molecular 
mechanisms of a metabolic process of energy expenditure called adaptive thermogenesis has 
gained enormous attention in the last two decades as a potential target to promote a negative 
energy balance62,63. Adaptive thermogenesis increases energy expenditure in brown adipose 
tissue (BAT) through the production of heat in response cold or over-feeding. 
 
1.3 ADAPTIVE THERMOGENESIS AS A THERAPERUTIC STRATEGY 
 BAT is a specialized adipose tissue that has been identified as a potential therapeutic 
target in obesity due to its ability to burn lipids in response to cold stress during adaptive 
thermogenesis. Thermogenesis is performed predominantly by the adipose tissues and 
maintains euthermia during exposure to low environmental temperatures. During short term 
exposure, skeletal muscle contributes to heat production via shivering thermogenesis, but 
adipose tissues are required for chronic acclimation to cold via adaptive thermogenesis64,65. 
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Recently, functional BAT was discovered in healthy human adults. This tissue is particularly 
interesting in the context of energy metabolism because it is characterized by high rates of 
glucose uptake and lipid oxidation. BAT is the main site of adaptive thermogenesis in rodents, 
and while there are important differences between human and murine BAT, healthy adult 
humans also retain functional BAT later into life. The amount of BAT in humans is 
proportionally much smaller than the amounts seen in rodents, but the molecular mechanisms 
and basic function are very similar66. In the face of hypothermic stress, the hypothalamus 
receives sensory inputs from the skin indicating cold exposure and mounts a thermogenic 
response to ensure that body temperature is maintained within a tight range. This process is 
essential to maintain homeostasis in cold environments or during overfeeding and is called 
adaptive thermogenesis. The activity of human BAT is decreased with age67 and in obesity68, 
which suggests a that loss of BAT function may exacerbate or contribute to the development 
of obesity. As such, the BAT may hold promise in restoring energy balance in obese and 
overweight individuals by increasing energy expenditure using the thermogenic pathway. 
 Some adipocytes in WAT depots in humans and rodents are susceptible to 
physiological changes that cause them to behave more as energy expending brown adipocytes 
than energy storing white adipocytes. This includes a stark change in adipocyte morphology to 
multilocular lipid droplets, higher mitochondrial density, and increased thermogenic protein 
expression of uncoupling protein 1 (UCP1). A similar, though less dramatic, acclimatory 
process can be seen in brown adipocytes in response to cold exposure (Figure 1.2). This shift 
in metabolic function has been termed “browning” and occurs as a natural thermoregulatory 
mechanism in WAT of mice but its extent and physiological significance have not been 
thoroughly studied in humans. This intermediate type of adipocytes is called brown-in-white  
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Figure 1.2. Representative histological adipose tissue sections and stylized representative adipocyte morphology 
to show the process of cold acclimation (browning) in murine brown adipose tissue. Thermoneutrality for mice is 
30°C, while full cold acclimation is defined here as 4°C for 3.5 weeks. In the histological sections, nuclei are 
stained purple by hematoxylin, cytoplasm is stained pink by eosin, and lipid droplets appear as white empty space.  
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“brite”, or “beige” and can be induced in the omental and, to a lesser extent, subcutaneous 
adipose tissue of humans69-73. Beige adipocytes are distinct in origin from brown adipocytes 
because they appear in WAT depots and their precursors lack myogenic factor 5 expression 
seen in brown adipocytes74 and myocytes. Like white adipocytes, brown and beige adipocytes 
are targets of hypothalamus-controlled sympathetic nerve activation and induction of lipolysis. 
In contrast to white adipocytes, norepinephrine binding to thermogenic adipocytes additionally 
activates the inner mitochondrial membrane protein, uncoupling protein 1 (UCP1). This proton 
shuttle uncouples ATP production from mitochondrial respiration, releasing potential energy 
in the form of heat64,65,75,76. Since the proportion of WAT to body mass in humans is large, and 
the proportion of BAT is small, the process of browning has received attention as a potential 
target for substantially increasing metabolic rate in humans to induce negative energy balance 
and ameliorate obesity. As with many other processes related to energy expenditure, evidence 
suggests thermogenesis is largely under hypothalamic control, in coordination with other 
centres in the brain77,78. 
 
1.4 CENTRAL REGULATION OF HOMEOSTASIS INCLUDING 
THERMOGENESIS 
 A diverse array of stressors can disrupt energy metabolism, including psychological, 
physical, thermal, and nutrient stressors. Homeostasis requires that these complex signals be 
received and correctly interpreted by the central nervous system so that a coordinated response 
can be made to rebalance the body79. The peripheral nervous system detects stressors and relays 
information to the brain where the signal is integrated, and the appropriate physiological and 
behavioural changes are initiated. The hypothalamus and the brain stem are known for 
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managing nutrient imbalance by regulating food intake80, and the hypothalamus is the main 
energy expenditure regulating centre81 that can mediate responses such as feeding behavior, 
physical activity, metabolic rate and thermogenesis. The hypothalamus utilizes endocrine and 
nervous systems to communicate with effector organs in the periphery to achieve these 
outcomes. The key energy regulating pathways initiated by the hypothalamus are the 
hypothalamic-pituitary-adrenal axis (endocrine) and the autonomic nervous system 
(neuroendocrine). These axes are essential for survival. 
 Neurons in the hypothalamus respond to internal and external stimuli by secreting 
releasing hormones into the hypophyseal portal system of the pituitary stalk, which carries 
these endocrine factors the short distance from the base of the hypothalamus to the anterior 
pituitary79. In this way, neuroendocrine factors connect the CNS to the peripheral endocrine 
systems via the pituitary. The hypothalamic-pituitary-adrenal (HPA) pathway is initiated by 
the release of corticotropin releasing hormone (CRH) from the hypothalamus, which acts on 
corticotrophs of the anterior pituitary, which release adrenocorticotropic hormone (ACTH) into 
the blood and acts on cells of the adrenal cortex to stimulate the synthesis and release of 
cortisol79. 
 The autonomic nervous system (ANS) is a key stress pathway under hypothalamic 
control that responds to physiological stressors without conscious thought. The autonomic 
nervous system is split into two branches: the sympathetic and parasympathetic nervous 
systems (SNS, PNS). The SNS is commonly known for the “fight or flight” response that is 
elicited by situations of physiological or psychological stress. This includes important roles of 
the SNS in maintaining body weight and temperature in the face of stressors such as nutrient 
excess and cold exposure, respectively. For example, when faced with hypothermia or 
overfeeding, the SNS induces energy expenditure through increased cellular metabolism, 
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burning energy and producing heat via adaptive thermogenesis. The PNS is traditionally 
thought of as the “rest and digest” arm of the ANS, but this paradigm has shifted to the 
understanding that both arms of the ANS work in concert to maintain a homeostatic balance. 
Hypothalamic energy regulation is further complicated by the incorporation of many endocrine 
factors that act on the brain or effector organs to modulate the energetic state. 
 
1.5 PACAP: A NOVEL ENDOCRINE REGULATOR OF ENERGY METABOLISM 
 Miyata, et al. 82 were searching for peptides of the hypothalamus that stimulate a 
physiological response in the pituitary, which would implicate them in the HPA axis or other 
hypothalamic-pituitary-end organ axes. This led to their discovery of pituitary adenylate 
cyclase-activating polypeptide (PACAP) in 1989, which was named for its ability to stimulate 
adenylyl cyclase in the pituitary. PACAP has since been characterized as a high-level regulator 
of the stress response including the endocrine HPA axis and the SNS. The literature around 
this neuropeptide has exploded, gaining considerable attention for its pleiotropic regulatory 
activity and therapeutic potential. 
 PACAP belongs to the Glucagon/Secretin Superfamily of proteins and shares 68% 
amino acid sequence similarity with vasoactive intestinal peptide (VIP). VIP and PACAP share 
traits common to their Superfamily, such as C-terminal amidation, random N-terminal coils 
and C-terminal alpha-helices. PACAP is encoded by the ADCYAP1 gene and is translated as 
a 176aa precursor, which is then spliced into the mature PACAP peptide as one of two forms: 
PACAP38 and PACAP27. A suite of enzymes is responsible for the variable processing of 
preproPACAP, contributing to the diverse actions of PACAP83. The highly conserved 
biologically active 27 N-terminal residues of PACAP38 constitute PACAP27, though 
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biological activity for certain receptors differs slightly between the two forms. Investigations 
of PACAP’s evolutionary history have shown conservation in amino acid sequence among 
taxa that diverged over 700 million years ago84. This strict conservation across diverse 
evolutionary groups aligns with a fundamental role in the maintenance of homeostasis. 
 PACAP is widely expressed in the CNS, PNS, and in many peripheral organs. In the 
CNS PACAP occurs in the brainstem nuclei, hypothalamic nuclei, amygdala, thalamic nuclei, 
cerebral cortex, medulla oblongata, posterior pituitary, thalamus, and nerves in cerebral blood 
vessels. PACAP is most highly expressed in the hypothalamus, specifically in the 
paraventricular, periventricular, ventromedial (VMH), suprachiasmatic, and supraoptic 
nuclei85. PACAP behaves as a hypothalamic releasing hormone and is actively transported to 
the anterior pituitary via the hypothalamic-hypophyseal portal system86 to illicit secretions of 
the pituitary. In the autonomic nervous system, PACAP is best known for its expression in 
preganglionic neurons of the sympathetic and parasympathetic nervous systems. For example, 
PACAP is the primary neurotransmitter released from neurons at the sympathetic 
adrenomedullary synapse and required for sustained secretion of norepinephrine87-89. PACAP 
is widely distributed in the peripheral organs, occurring in (but not limited to) exocrine and 
endocrine glands, immune cells, gonads, pancreas, and the genitourinary tract. 
 PACAP mediates its effects through three distinct receptors, which are expressed in all 
major organ systems in the body and thus, PACAP regulates diverse physiological functions. 
Furthermore, the downstream activation of signaling pathways differs by cell/tissue type to 
allow fine-tuning of the physiological response in different contexts. The PACAP receptors 
have been cloned and are called PAC1R (495 amino acids)90, VPAC1 (457aa)91 and VPAC2 
(438aa)92, here collectively referred to as PACAP receptors. PAC1R mRNA is most abundant 
in the brain, pituitary, and adrenal gland and tissues expressing PAC1R have distinct profiles 
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of PAC1R splice variants. VPAC 1 and 2 are most abundant in the lung, liver, and testis83. All 
three are class B GPCRs. Since many clinically utilized pharmaceuticals target GPCRs, the 
PACAP receptors have received significant attention for their therapeutic potential. 
 Differential splicing of the receptors may increase the targeting ability of 
pharmaceuticals by taking advantage of differential binding affinities and physiological 
outcomes to reduce off-target effects. The PAC1R receptor is highly spliced, having at least 
11 known isoforms in rodents and 9 in humans93. All PAC1R isoforms are selective for PACAP 
over VIP yet the affinity of the 27- and 38-amino acid version of PACAP differs based on 
PAC1R splice variant83. Splice sites occur at several points93 within the receptor structure and 
mediate the removal of a 21aa segment in the extracellular domain and in some variants. 
Additionally, a set of cassettes called HIP (28aa), HOP1 (28aa) and HOP2 (27aa) can be 
independently inserted or absent (PAC1Rnull) in the third intracellular loop to create a variety 
of spice variants94. Each splice variant is functionally distinct in its binding affinity for certain 
ligands, its intracellular signaling components94, and specific distribution93. For a list of the 
variants and their downstream signaling, see Dickson and Finlayson 84. Maxadilan is an 
unrelated peptide isolated from the sandfly, Lutzomyia longipalpis, that has been characterized 
as a potent, specific PAC1R agonist95 while a shortened version of Maxadilan, called M65, 
offers a selective antagonist for PAC1R96. Their specificity for PAC1R over VPAC1/2 
illustrates the potential precision of pharmaceutical development in this area and these peptides 
provide an invaluable tool for studying the biological activity of PACAP receptors. 
 All three PACAP receptors are associated with stimulatory G-proteins (Gs and Gq) as 
well as inhibitory G-proteins (Gi). Gq leads to increased cytosolic Ca2+ through the activation 
of phospholipase C (PLC) and, subsequently, inositol triphosphate (IP3). Gs causes the 
activation of adenylate cyclase, PACAP’s namesake, whose activation has a number of 
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downstream effects. This includes activation of PKA, Rap guanine nucleotide exchange factor 
4 (Rapgef4), and Rapgef2, which contribute to inhibition of the apoptotic pathway involving 
caspase 9 and 3, p38-mediated cell arrest, and neuritogenesis97. Rapgef4 also regulates cAMP 
response elements via cAMP response-element binding protein (CREBP)83. Gi has an 
inhibitory effect on adenylate cyclase and therefore decreases production of cAMP. Thus, 
differential activation of coupled G-proteins adds yet another level of control for downstream 
response to activation of PAC1R.  
 The extensive functions of PACAP in many tissues and cells types have been reviewed 
thoroughly elsewhere83,84. Thus, they will be only briefly highlighted here to showcase the 
diverse actions of this neuropeptide. In the nervous system, PACAP acts as a non-
noradrenergic, non-cholinergic, mostly preganglionic neurotransmitter. In the central nervous 
system, PACAP acts as a neurotransmitter, neuromodulator, and neurotrophic factor and in the 
peripheral nervous system, as a neurotransmitter or neuromodulator regulating sensory stimuli 
and endocrine secretion98. In the circulatory system, PACAP is a potent vasodilator. In the 
endocrine system, it is an essential neurohormone with roles in regulation and production of 
other endocrine factors, such as catecholamines from chromaffin cells of the adrenal medulla 
and glucagon from pancreatic b-cells in response to hypoglycemia88,99. Coordination of these 
organ systems allows PACAP to contribute to neuroprotection, energy metabolism, 
catecholamine synthesis and release, nociception, circadian rhythms, headache pathology, 
stress-related pathologies, and neurological disorders. 
 PACAP’s roles in disparate processes can be unified under the understanding that many 
of these processes are responses to different types of stress. Thus, we can view PACAP as an 
important regulator of adaptive and maladaptive responses to stress100. Stress can be defined 
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here as any internal or environmental threat to homeostasis and may include both physiological 
stressors and psychological stressors. For example, independent research performed by Lee 
Eiden and Victor May has demonstrated evidence that PACAP is involved in the response to 
emotional stress101,102. One such study showed that compared to wild-type controls, PACAP-
null mice have significantly reduced activity in the hypothalamus and concomitantly lower 
plasma corticosterone103, in response to physical restraint or light-induced stress. This result 
suggests that PACAP enhances the emotional stress response. In the context of physiological 
stressors such as cardiac injury, PACAP has displayed protective, anti-apoptotic effects on 
myocytes and increased the survival of mice following induced cardiac injury104. These and 
other studies have contributed to the conclusion that PACAP acts both centrally and 
peripherally to regulate the response to stressors of very different types. 
 
1.6 THESIS SCOPE AND SIGNIFICANCE 
 Our research group is particularly interested in the role of PACAP in energy regulation 
in the brain, where it is most highly expressed in the hypothalamus and its expression has been 
demonstrated in a number of hypothalamic energy-regulating nuclei including the arcuate 
nucleus (ARH) and VMH105,106. As an energy regulating centre, the hypothalamus protects 
euthermia through the initiation of the thermogenic response, which burns fat to increase body 
temperature in the face of cold stress. Mouse pups lacking PACAP experience higher mortality 
due to hypothermia, even at room temperature (21°C) and adult mice lacking PACAP do not 
exhibit a full thermogenic response to norepinephrine stimulation of the BAT107,108, which is 
the primary thermogenic organ in mice. Pharmacological studies have outlined a role for 
PACAP in the VMH as an activator of thermogenic signal, but these studies109,110 used a single 
supraphysiological dose of PACAP or Maxadilan injected into the VMH in unreported 
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volumes and may not represent normal physiological action of this peptide in the 
hypothalamus. Thus, a targeted approach to genetic introduction of PACAP selectively into 
the VMH under control of an endogenous promoter is needed to understand the true 
physiological effect of PACAP action directly in the VMH. The development and verification 
of this genetic tool in the central nervous system will be the focus of Chapter 2. 
 To gain a more comprehensive understanding of the scope of PACAP’s energy 
regulating actions, it will also be necessary to investigate the contribution of PACAP’s 
peripheral activity. As mentioned above, adipose tissue is an important target of SNS outflow 
tracts that regulate responses to changes in energy status or thermogenic requirement. 
Sympathetic postganglionic nerves innervate the adipose tissues and act though GPCRs on 
adipocytes, stimulating responses including induction of lipolysis and thermogenic pathways. 
However, the role of PACAP-mediated thermogenesis by PACAP binding PAC1R directly at 
the level of the adipocyte has not yet been investigated. This may be, in part, due to the 
literature lacking comprehensive data about the expression of each of the receptors in adipose 
tissue of mouse and humans. In order to fully understand PACAP’s regulation of the 
thermogenic response in brown and beige adipocytes, it is necessary to characterize the 
expression and function of PACAP and PACAP’s receptors (PAC1R, VPAC1, and VPAC2) 
in thermogenic adipose tissues. Novel characterization of PACAP receptor expression and 
PACAP activity in the context of adipose tissues will be the focus of Chapter 3. 
 Worldwide obesity prevalence has reached unprecedented levels with its comorbidities 
in tow. This epidemic puts unmanageable demand on health care systems and introduces 
significant patient suffering. Physiological factors contribute to the development and 
maintenance of the obese state and provide promising therapeutic targets. To manage this 
disease, a stronger understanding of the central and peripheral mechanisms of energy 
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regulation must be achieved. This includes the study of adipose tissue in its role as a modulator 
of whole-animal energy status and the pathophysiological consequences of malfunctions in this 
tissue. Especially promising is the possibility of harnessing adaptive thermogenesis in adipose 
tissues to curb energy excess in overweight and obese individuals to restore energy 
homeostasis. Here I describe the study of a novel neuroendocrine factor PACAP in the context 
of its regulation of energy balance and explore the possibility that PACAP modulates energy 
expenditure peripherally by binding to adipose tissue. 
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Chapter Two: Developing an in vivo Model to Assess the Role of 
PACAP in VMH-Mediated Thermogenesis  
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2.1 INTRODUCTION  
 The hypothalamus is a key centre in the control of energy metabolism including 
appetite and energy expenditure such as thermogenesis. Therefore, the hypothalamus is an 
important brain region to consider when developing therapeutic approaches to obesity 
treatment. In terms of mass, the hypothalamus accounts for less than one third of one percent 
of the human brain79. Despite its small size, this brain region is critical for the maintenance of 
homeostasis in response to changes in the internal and external environment including the 
control of body energy stores through the regulation of satiety, physical activity and body 
temperature, and other dynamic processes such as blood pressure, reproduction, and growth. It 
is bilaterally organized and symmetrical, with each side a functional duplicate of the other111. 
The role of the hypothalamus in maintaining vital biological functions such as water balance 
points to the evolutionary advantage of such redundancy. Human patients with congenital or 
trauma-related lesions that affect both sides of the hypothalamus develop obesity in 25% of 
cases112. The regulation of energy balance by the hypothalamus is critical to basic biological 
functioning, but many of the neural circuits that underlie its functioning remain unmapped. 
  In the anterior/posterior axis, the hypothalamus can be divided broadly into three areas: 
the preoptic (anterior), tuberal (median), and posterior. Each area consists of distinct patterns 
of neural input, integration, and output. The preoptic area is an important integrator of 
thermoregulatory signals, reproductive behaviour, circadian rhythms, and electrolyte 
balance113. The tuberal region integrates satiety and feeding signals. Its outputs include 
mediators of reproductive behaviour, endocrine secretions, and other autonomic functions such 
as thermogenic activation, which will be the focus of this chapter. The posterior area’s outputs 
include wakefulness, alertness and stress113. 
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 The hypothalamus is further subdivided into a diverse collection of semi-discrete units 
known as nuclei. In the CNS, the word nucleus refers to an organized group of neurons that 
work in concert to regulate metabolic, behavioural, and endocrine functions to ensure 
homeostatic balance. In the context of thermogenesis, the posterior hypothalamic nucleus is 
involved in the response to both hypothermia and hyperthermia. The medial, or tuberal region, 
includes the dorsomedial (DMH), ventromedial (VMH), paraventricular (PVH), and arcuate 
(ARH) nuclei (Figure 2.1) that collectively mediate thermogenesis, while lateral areas of the 
hypothalamus initiate heat dissipation mechanisms111. Significant progress has been made in 
attributing functional roles to nuclei in the hypothalamus81. However, a great deal of work 
remains to be done before a comprehensive functional map can be composed of this highly 
integrated, interconnected brain region114. This is partially due to the diverse and sometimes 
overlapping range of physiological roles that nuclei play as well as the pleiotropic activity of 
the genes they express115. In fact, the exact functions and boundaries of the hypothalamic nuclei 
in scientific literature are somewhat disputed116. In order to inform therapies targeted at energy 
regulation mechanisms such as adaptive thermogenesis, an increased understanding of the 
exact roles and boundaries of the DMH, VMH, ARH, and PVH in thermogenic activation are 
needed. 
 Increasing interest in energy regulating axes due to the rise in obesity, has spurred 
exciting work in the last 30 years that has delineated a complex pattern of cooperativity 
between the hypothalamic nuclei, in integrating and mediating neurochemical responses to 
homeostatic threats including nutrient and thermal stress. Despite the large body of literature 
describing orexigenic and anorexigenic signaling in the hypothalamus, only a small amount of 
this information will be described here as it pertains to energy regulation by a few of the tuberal 
nuclei and preoptic nuclei. 
 27 
 
 
 
Figure 2.1. Cross-sectional images number 21 (a) and 72 (b) from the Allen Mouse Brain Reference Atlas (sagittal 
and coronal aspect, respectively) to show anatomical location of the hypothalami, coloured red. Inserts show 
enlargement of the medial hypothalamic region for spatial context and to show nuclei involved in thermogenesis, 
which include the dorsomedial (DMH), ventromedial (VMH), and arcuate (ARH) nuclei, but not the 
paraventricular (PVH) nuclei, which are positioned anterior of the others. Images collected from the following 
URLs with free, open access permission © Allen Institute. 
(a) © [2004] Allen Institute for Brain Science. Allen Mouse Brain Reference Atlas, Sagittal. Available from: 
https://mouse.brain-map.org/experiment/thumbnails/100042147?image_type=atlas 
(b) © [2004] Allen Institute for Brain Science. Allen Mouse Brain Reference Atlas, Coronal. Available from: 
https://mouse.brain-map.org/experiment/thumbnails/100048576?image_type=atlas  
 
  
a b
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 The study of neuropeptides over the last few decades has elucidated some of the 
molecular mechanisms that explain the results of older studies, which ascribed satiety and 
feeding mediation to the VMH. Reduced VMH function in rats has been associated with 
maladaptive eating habits for half a century117,118. Destruction of the VMH in rodents leads to 
intense hyperphagia, whereas destruction of the lateral hypothalamic nuclei leads to severe 
hypophagia and dangerous weight loss111. It is now known that leptin and brain-derived 
neurotropic factor (BDNF) are key hormonal mediators of energy balance in the VMH111. 
Recently, overeating behaviour resulting from VMH damage was attributed to loss of leptin 
signaling in this nucleus and an associated induction of leptin production from the adipose 
tissue119, illustrating the importance of VMH leptin signaling in the control of energy balance. 
Injection of BDNF into the hypothalamus decreases food intake and causes gains in 
bodyweight irrespective of prior feeding or fasting120. BDNF supports neuron activity and 
cytogenesis into adulthood and has recently been associated with energy regulation due to 
genetic studies that described seven SNPs in and following the BDNF sequence that correlate 
with greater risk of obesity in humans121,122. The study of hormonal mediators of energy 
balance in the hypothalamus has thus provided promising targets and increased interest in 
hypothalamic regulatory peptides. 
 Other neuropeptides have been shown to regulate energy metabolism through the 
control of satiety. For example, PACAP action in the hypothalamus reduces food 
intake109,123,124, perhaps by the induction of proopiomelanocortin (POMC) expression109, 
reduction of orexigenic Agouti-related peptide (AgRP)125 or regulation of anorexigenic 
neuropeptide Y (NPY) in neurons of the ARH126, where PACAP, PAC1R, and VPAC2 are 
expressed126,127. PACAP mRNA expression is increased in the hypothalamus of mice fed high-
fat diet compared to chow fed control mice, linking PACAP expression in the hypothalamus 
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to nutrient status and suggesting that PACAP could play a role in resisting maladaptive changes 
in body weight106. PACAP protein is expressed in the PVH, periventricular, VMH, 
suprachiasmatic, and supraoptic nuclei85, further supporting its role in regulating energy 
metabolism including thermogenic activation in the hypothalamus. Thus, PACAP is surfacing 
as an important neuropeptide in the regulation of appetite in the hypothalamus. 
 The neuronal origins of the neurochemical signals for induction of adaptive 
thermogenesis in adipose tissue have also become clearer as techniques to study molecular 
structure and function have improved. The preoptic anterior region of the hypothalamus has 
temperature sensing neurons that can detect and initiate responses to minute changes in body 
temperature128. More recently, the importance of cold-sensing neurons in the brain has been 
called into question and some authors suggest that the activity of these cold-sensing neurons 
actually results from regulated input of signals from the preoptic warm-sensing neurons116,129, 
which have been shown to co-express PACAP and BDNF128. Peripheral neuronal cold sensors, 
on the other hand, predominate over peripheral warm-sensing neurons and allow the detection 
of cold at the level of the skin and extremities116. Both cold and warm sensing peripheral 
neurons express transient receptor potential (TRP) ion channels, including vanilloid 1 (TRPV1) 
for hot and melastatin (TRPM8) for cold130. A number of other TRPs exist, with limited 
information available about their function. Once cold or warm-sensing inputs are passed 
through the preoptic area (anterior) of the hypothalamus, they are integrated by the tuberal 
(median) area of the hypothalamus, where illuminating functional data has been obtained 
through both pharmacological and electrical/chemical means using stereotaxic targeting 
strategies. 
 Stimulation of various nuclei of the hypothalamus including the DMN, VMH, PVN, 
and ARH through electrical or pharmaceutical means leads to increased sympathetic outflow 
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and induction of adaptive thermogenesis in the brown adipose tissue (BAT)77,78,131,132. Injection 
of PACAP into the VMH, but not the PVH, increases sympathetic output to BAT, and this 
effect is attenuated by prior treatment with PACAP receptor antagonists110. Viral tracing 
studies have shown that the sympathetic fibres, which innervate thermoeffector organs such as 
the BAT, originate in the sympathetic ganglia in the intermediolateral column of the spinal 
cord116. These receive input from the medulla, which in turn receives input from the 
hypothalamus116. Interestingly, viral tracing studies have failed to indicate the VMH as a direct 
source of thermogenic signaling via sympathetic innervation to the BAT133-135 despite its well-
established role in activating adaptive thermogenesis gleaned from functional data77,131,136. One 
important limitation of the retrograde viral tracing method is that its reach is restricted to 
approximately three neurons upstream137. Given the interconnected nature of the hypothalamic 
nuclei, it would be unsurprising were the thermogenic signal passed from the VMH onto other 
nuclei before leaving the brain through the brainstem, thereby positioning the VMH upstream 
from the maximum reach of the retrograde viral method.  
 Pharmacological injections into the VMH using PACAP have been successful in 
eliciting a thermogenic response at the BAT, but as mentioned in Chapter 1, these injections 
have a number of drawbacks. Volumes of the injections were not reported, supraphysiological 
doses were used, and single injections only provide acute effects, and thus long-term 
consequences could not be determined. It is clear that other experimental approaches are 
required to target the VMH and provide data to address these issues. Gene therapy has gained 
traction as a clinically relevant technique138 and a useful tool in functional genomics, which 
introduces a functional copy of the gene to the host cells. Importantly, the expression of genes 
delivered by the virus can be controlled by endogenous host cellular machinery such as 
promoters. This benefit of this approach is twofold: endogenous cell- or tissue- specific 
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transcription factors induce the expression of genes at physiological levels, as well as 
restricting expression of the gene of interest to a target cell population thus reducing off-target 
effects.  
 Self-complimentary adeno-associated viruses (scAAVs) offer a promising solution to 
problems normally ascribed to gene therapy, including immune response, size restrictions of 
genes to be introduced, and disruption of the host genome upon viral gene insertion138-140. 
Biotechnological advances in viral packaging have allowed greater and greater plasmid size, 
meaning that genetic sequences over 5kb can transported reliably into host cells. AAVs induce 
a very low or undetectable immune response, which is essential to prevent lesioning in brain 
tissue following viral administration. Tissue-specific serotypes of AAVs, that preferentially 
infect particular tissue or cell types, further increase the accuracy of targeted gene delivery. 
AAV serotype 9 (AAV9) has been proven effective in vivo and in vitro for gene delivery139,141 
and favors neurons and glial cells. When injected into the CNS, there is little chance of the 
virus escaping the brain and delivering genes to unintended targets due to their unique inability 
to replicate independently without an accompanying adenovirus140. AAVs have an 
extrachromosomal mode of gene delivery that minimizes the risk of disrupting the host 
genome. Thus, the introduced genetic material acts as an auxiliary piece of genetic material 
that does not interact with the host genome. Preferential infection of AAVs to a specific tissue 
type, coupled with target-specific promoters allows for a high degree of expression specificity 
and has been successfully used to target gene expression in discrete populations of neurons in 
the CNS, including nuclei of the hypothalamus142. 
 Stereotaxic intracerebral injection strategies for viral delivery of genetic material offer 
a very promising tool to study the functional role of PACAP in VMH-mediated thermogenesis, 
using the neurophilic AAV9 and a VMH-specific promoter. Direct injection into the target site 
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overcomes multiple difficulties that are encountered when trying to deliver viral particles to 
the brain via the blood with peripheral injections. To protect the brain from infection or 
damage, the blood-brain barrier prevents entry of a number of particles with therapeutic 
applications including viruses, greatly reducing pharmacological efficacy and demanding 
larger doses140. Therapies harnessing viral vectors can also suffer from undesirable 
accumulation of viral particles in the liver140 that prevents their delivery to the brain and can 
increase gene delivery to hepatocytes and other cells of the liver at high local AAV 
conentration143. Stereotaxic intracerebral delivery provides a number of advantages over 
peripheral administration and coupled with a VMH-specific promoter could deliver PACAP to 
that nucleus with very high specificity and efficacy. 
 
Steroidogenic Factor 1 promoter as a VMH-specific genetic tool 
 Steroidogenic factor 1 (SF1) is an exciting molecule for studying hypothalamic 
function because its expression is restricted to steroidogenic tissues such as neurons of the 
VMH, with little or no expression in other brain areas144 and its expression is maintained 
throughout life as evidenced by multiple genetic models105,145,146. SF1, or nuclear receptor 
subfamily 5 group A member 1 (NR5A1), is a transcription factor that is essential in regulating 
reproductive development at all levels of the hypothalamic-pituitary-gonadal axis136,146,147 
including neurons of the VMH that regulate both metabolism and fertility148. SF1 and its 
promoter reside in the NR5A1 5’ regulatory region149 at LOC108489981 on chromosome 2, 
(NCBI: NG_051341.1). Evidence suggests that the promoter for SF1 is located at position 
3701-3783147, while SF1 itself is a 462 aa protein with a transcription start site at 3784. Genetic 
studies investigating the effects of SF-1 knockout have been performed at multiple levels of 
this axis in an attempt to isolate primary and secondary effects of SF1 loss, which produces a 
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complex phenotype of dysregulated endocrine functioning caused by absence of a developed 
VMH and adrenal glands, and greatly underdeveloped reproductive structures150. 
 Mice with postnatal VMH-specific knockout have impairments in energy regulation, 
including hyperphagia, reduced thermogenesis, and decreased energy expenditure, leading to 
obesity136,151. This suggests that SF-1 is required for development of the VMH and steroid 
producing endocrine glands, and in adulthood is required for the maintenance of energy 
balance via the VMH. Pituitary gland-specific SF-1 knockout mice lack secondary sexual 
characteristics but have intact adrenal glands146. Leydig- or granulosa cell-specific knockout 
of SF-1 in either male and female mice, respectively, leads to sterility in both sexes and in 
males results in hypoplasia of testes and retention inside the body cavity152, indicating the 
development of gonads relies on cell-specific SF-1 expression. Whole-animal and CNS-
specific SF-1 knockdown studies show that SF-1 is important in the structural organization of 
the VMH153 and its connections with surrounding nuclei154. To account for secondary effects 
of gonad-derived hormone secretion, an SF-1 knockout model was augmented with adrenal 
gland transplants to better understand the contribution of SF1 produced in the VMH. This 
model showed obesity and reduced leptin receptor expression in the VMH136. Thus, SF1 
expression in the hypothalamus is key to energy balance including the activation of 
thermogenesis. 
 Rodent models of global PACAP knockout have been developed by Gray et al.108 and 
others, allowing the characterization of a phenotype with impaired thermogenic capacity and 
nutrient metabolism. This model is complicated, however, as PACAP is ubiquitously expressed 
and global knockouts have multifaceted impairments in high-level regulation of stress circuits 
in the CNS including the hypothalamic-pituitary-adrenal (HPA) axis as well as being an 
important neurotransmitter and neuromodulator at the level of the effector organs such as the 
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pancreas and the adrenal medulla. Furthermore, overall neuron survival and function is likely 
reduced  in this model due to the loss of PACAP’s neuroprotective and neurogenerative effects 
in the CNS155. Genetic rescue of PACAP in specific nuclei of the hypothalamus in the context 
of a global PACAP knockout will help elucidate primary and secondary effects of PACAP in 
this complex phenotype.  
 This chapter has emphasized an integral role of PACAP in the thermogenic pathways, 
the importance of SF-1 in the development and thermogenic function of the VMH and has 
demonstrated a need for further study of the thermogenic nuclei. Thus, we propose that a 
genetic construct be developed to express PACAP specifically in the VMH under the control 
of the SF-1 promoter. 
 
We hypothesize that genetic restoration of PACAP specifically in the VMH will rescue the 
impaired thermogenic phenotype observed in PACAP-/- mice. 
 The objectives of this chapter are the following: 
AIM 1: Develop a protocol for stereotaxic intracerebral and intracerebroventricular injection 
 surgery and perform injections of scAAV9 viral vectors into the third ventricle or 
 VMH of mice, respectively. 
AIM 2: To assess the performance of the scAAV9 viral vector carrying its genetic cargo, 
 pscAAV9-SF1-GFP, in activating VMH-specific induction of EGFP expression in 
 vitro. 
This work will support development of an in vivo rodent model to study PACAP’s role in the 
hypothalamic control of energy metabolism including feeding behaviour and thermogenesis. 
These insights will help inform treatment strategies in obesity by elucidating the complex 
interplay of hypothalamic nuclei in maintaining energy balance. 
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2.2 MATERIALS AND METHODS 
Animals 
 Adult (12-week-old), male C57BL/6 mice were bred at the Northern Health Sciences 
Centre, UNBC. These mice were sourced from a PACAP-null mouse line previously generated 
by Gray, et al. 108 backcrossed to a C57BL/6 background, with PACAP+/+ mice selected for the 
study. Mice were housed two per cage with sterile corncob bedding and placed on a 12-h light 
to 12-h dark cycle (lights on 0700–1900 h). Animals had unlimited access to water and 
standard rodent chow diet (LabDiet 5001, LabDiet, Inc., Brentwood, Leduc, AB, Canada; 
metabolizable energy 3.02 kcal/g). Body mass (g) was measured twice weekly to detect 
potential declines in mouse health. Care and treatment of mice was in accordance with the 
guidelines of the Canadian Council on Animal Care, and protocols for the study were approved 
by the University of Northern British Columbia’s (UNBC) Animal Care and Use Committee 
(ACUC). 
 
Construction of the pscAAV-SF1-GFP plasmid 
 The pAAV-CMV-GFP was developed and deposited at Addgene (Watertown, MA, 
USA) by Gray and Zolotukhin 156. We obtained the plasmid (Addgene plasmid # 32396) in the 
form of an Escherichia coli agar stab, which was grown up and the plasmid isolated according 
to the supplied Addgene protocols as described in McMillan 157. The putative SF1 promoter 
sequence, 3706 – 4095bp of NR5A1, was amplified, cloned into a pGEM-T Vector (Promega, 
Madison, WI), and sequenced (University of Northern British Columbia’s Northern Analytical 
Laboratory Services).  
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The resulting pGEM-T-SF1 plasmid and the pscAAV-GFP plasmid containing CMV promoter 
were used to create the pscAAV-SF1-GFP plasmid (Figure 2.2) that was packaged into a self-
complimentary AAV serotype 9 (scAAV9) viral vector (Vigene Biosciences, Rockville, MD, 
US). 
 The scAAV9 vector was chosen for its extra-chromosomal plasmid DNA delivery 
method, low stimulation of immune response, lack of self-replication, and long-term stability 
of the delivered DNA. Since this vector will not incorporate in the host DNA, there is very 
little chance of off-target effects resulting from the interruption of host genes. 
 
Viral Dosage Calculations  
 Dosages for self-complementary AAV9 virus vary greatly in the literature. For 
example, some report injection volume without a viral titre158, others report the number of viral 
particles159, or viral genomes (vg) per kg of body mass139, but many do not report volume, 
which is an important factor for ICV injections where small volumes are required to prevent 
changes in intercranial pressure. Meyer et al. (2015)139 reported significant genetic rescue in a 
knockdown model for spinal muscular atrophy using 3.3e14 vg/kg as their highest viral dose. 
They found significant response at 1.8e14 vg/kg, though increased survival time due to restored 
gene delivery was approximately half. We received our virus (scAAV9-SF1-GFP) at a titre of 
2.24e14 vg/mL, and thus for these initial studies testing expression and specificity of the virus, 
opted to inject 0.8-1 μl of undiluted virus per mouse, resulting in a dose of 7.7e12 vg/kg (ICV) 
or 8.6e12 vg/kg (VMH). 
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Figure 2.2. Simplified workflow process demonstrating the development of the pscAAV plasmids used in this 
chapter. Addgene Plasmid # 32396 (top left) contains the cytomegalovirus promoter (CMV) and EGFP. The 
pscAAV-SF1-GFP virus was developed by removal of CMV via restriction enzyme digest (1) followed by 
insertion of the steroidogenic factor 1 promoter (SF1). This control plasmid was created to facilitate 
characterization of in vivo viral vector expression following injection into the brain and should only be transcribed 
in neurons of the ventromedial nucleus of the hypothalamus, since SF1 expression in the brain is restricted to the 
VMH. The experimental virus was developed by restriction enzyme digest (2) of the control plasmid to remove 
EGFP and replace it with pituitary adenylate cyclase-activating polypeptide (PACAP). Plasmid maps were created 
in part using the online Benchling Plasmid tool (Benchling, Inc., San Francisco, CA, USA). 
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Stereotaxic Surgery and delivery of scAAV9-SF1-GFP  
 This procedure was adapted from the UNBC ACUC, Standard Operating Procedures, 
A3-4: Mouse Stereotaxic Surgery. 
 In preparation for surgery, mice were weighed and a 1 cm patch of fur was shaved from 
the scalp of the mouse. Mice were deeply anaesthetized with isoflurane (1 L/min O2, 5% 
isoflurane) and placed in a stereotaxic ear bar apparatus. The left ear canal of the mouse was 
then placed over the left ear bar (set to 3.5 mm for C57BL/6), then the right ear bar was inserted 
into the right ear canal. The mouse was checked to ensure correct positioning by lightly pushing 
on the left and right side of the mouse’s snout to ensure no lateral movement. If the mouse was 
secure, the right and left ear bars were alternately adjusted in the y-axis to ensure that the 
measurements of each ear bar were equal (Figure 2.3a). Once centered, the incisor bar was 
locked carefully in place and the anesthetic mask positioned to cover the snout to restore 
isoflurane anesthesia at a surgical plane (1 L/min O2, 2% isoflurane). 
 After 2 minutes, anesthesia level was assessed by toe pinch and a rectal probe was 
inserted to track body temperature and control the automatically adjusting safe heat pad to 
maintain body temperature during the surgery. The surgical site was cleaned three times (70% 
isopropyl alcohol swabs) and mice were given Ringer’s lactate solution (0.3 mL) 
subcutaneously. A line block was injected subcutaneously at the incision site (bupivacaine 
hydrochloride USP (2.5 mg/mL in Ringer’s Lactate solution (100 µL)), 10 min prior to making 
a 0.5 cm incision exposing lambda and bregma (Figure 2.3b). 
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Figure 2.3. Stylized diagram of stereotaxic surgery setup (a) and dorsal view of mouse skull suture lines, shown 
as red dashed lines (b), used as landmarks for intracranial injection of AAV9 viral vector bearing pscAAV9-SF1-
GFP. The entry point shown as a red dot approximates the location of drilling and needle insertion for the 
ventromedial nucleus of the hypothalamus (VMH)-targeted injection strategy. Diagram not to scale. 
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 Using the micropositioner arm of the stereotaxic stand, the height (z) of bregma and 
lambda were equalized by adjusting the incisor bar appropriately. A trephination through the 
skull was carefully made using a drill bit (1 mm diameter ball mill carbide) at pre-planned  
coordinates targeting the ventromedial nucleus of the hypothalamus (1.46 mm posterior of 
bregma and 0.39 mm lateral to the midline) ensuring no damage to the underlying tissue. 
Coordinates for the third ventricle were the same except directly at the midline, not 0.39 mm 
lateral to it. 
 The drill was replaced on the stereotaxic micropositioner arm with the zero dead 
volume Hamilton Syringe 7000 model 1 μL syringe and 69.9 mm-long needle with 0.515 mm 
outer diameter. To account for differences in size and lateral position of the drill holder and 
the syringe holder, the syringe needle was lowered until it touched the surface of the brain in 
the trephination and this became the starting point for the vertical coordinate (-5.7 mm in the 
z-axis). The injection assembly was lowered at a rate of 1 mm per minute until the planned 
coordinates were reached and 0.8-1 μl of undiluted (2.24e14 vg/mL) AAV9 viral particles 
carrying psc-AAV9-SF1-GFP was injected over 30 seconds and not withdrawn until 5 min 
after the injection to ensure adsorption of the fluid. The trephination was flushed with saline 
and excess saline removed with a sterile cotton swab. The incision was sutured (5-0 polyglactin 
910 braided suture on an RB-1 17 mm needle) under a sterile drape. 
 Following suturing, isoflurane was set to 0 and oxygen left at 1 L/min for approx. 10 
min. While the animal recovered from the anesthetic, lidocaine cream (2.5% w/v) was applied 
to the incision site, ear bars were removed and ear canals checked for damage, monitoring 
equipment was removed and the mouse was placed in a warmed cage with low light until 
normal behaviors, such as coordinated walking and grooming, returned (approx. 45 min). 
Long-term recovery and monitoring procedures were performed as outlined in UNBC 
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ACUC’s, Standard Operating Procedures A3-4: Mouse Stereotaxic Surgery and SOP A-40: 
Anaesthetic Depth and Monitoring. 
 Mice were “incubated” (meaning injected with virus then returned to normal housing) 
with the virus for 2.5 weeks before brain collection and analysis because the manufacturer 
(Vigene) reports that this timeline provides the maximal level of viral genome expression, 
which is expected to decrease over time. To assess the potential for long-term acclimation or 
developmental studies, a long-term incubation of 6 months was performed. This timeline 
encompasses the time of development from weaning until mid-adulthood and reveals whether 
this model is suitable for developmental studies to elucidate long-term effects of genetic rescue. 
 
AAV9-EGFP Brain collection and Imaging Protocol 
 Mice were anesthetized with 2.5% isoflurane delivered at 1 L/min oxygen. Surgical 
plane anesthesia was confirmed by lack of withdrawal from toe-pinch and absent palpebral 
reflex. An incision in the skin was made from the pelvis to the chin, then through the visceral 
peritoneum and up through the diaphragm and right side of the rib cage to the neck, exposing 
the heart. A 25 g needle attached to a syringe containing phosphate buffered saline was inserted 
into the left ventricle of heart. A 3 mm incision was made in the right atrium of the heart then 
the 10 mL of saline was injected over 4 min to flush the capillaries of autofluorescent 
erythrocytes. Following saline perfusion, isoflurane anesthetic was stopped. The empty syringe 
was replaced with one containing 10 mL 4% (w/v) formaldehyde, and the entire volume 
injected over 4 min. Fixation tremors and blanching of internal organs and brain were used as 
indicators of successful fixation. The brain and adrenal glands were collected and fixed in 4% 
formaldehyde for 8 hr and prepared for cryoprotection by placing them in 15% sucrose until 
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they sank, then switching to 30% sucrose before cryosectioning, mounting, and DAPI staining 
(Wax-It Histology, Vancouver, B.C., CAN).  
 Brain sections were mounted two or three per slide and the best-quality section was 
imaged on each slide. Sections with visible mounting artifacts were not imaged when it could 
be avoided. Images were acquired using AxioObserver.Z1/7 with Axiocam 503 camera with 
10X/0.30 M27 lens. For imaging on the DAPI channel, the following settings were used: LED-
Module at 385 nm, 28.40% intensity, 353 nm excitation, 465 nm emission, and 500 ms 
exposure. For the imaging on the FITC channel, the following settings were used: LED-
Module at 470 nm, 100% intensity, 488 nm exitation, 509 nm emission, and 1.1 s exposure. 
 
2.3 RESULTS 
 Two injection strategies were used in this study (Table 2.1): one intracerebral injection 
targeting the VMH, and one intracerebroventricular (ICV) targeting the third ventricle. For 
each strategy, a mouse was incubated with the virus for 2.5 weeks following the surgery, then 
brains were collected and analyzed for expression of enhanced green fluorescent protein 
(EGFP). An additional mouse was injected using the VMH-targeted strategy and incubated for 
6 months. 
 
ICV  
 The ICV injection strategy did not yield EGFP expression in any part of the brains after 
2.5 weeks, including the hypothalamus (Figure 2.4a).  
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Table 2.1. Stereotaxic injection strategies used for intracerebral injections of scAAV9 viral particles containing 
pscAAV9-SF1-GFP plasmid. Injections were targeted at either the ventromedial nucleus of the hypothalamus 
(VMH) or the third ventricle (V3) in volumes of less than 1 μL and the virus allowed to incubate for 2.5 weeks 
or 24 months before collection of brains to assess injection efficacy and longevity of the introduced plasmid gene 
expression. Mice were male C57BL/6, except VMH-24wk, which was from a line of SVJ mice 10x backcrossed 
to C57BL/6. 
 
 
 
  
Study ID Injection target Dose (vg/kg) Time (weeks) Age (d) UNBC ID Sex Mass (g)
V3-2.5wk V3 7.7e12 2.5 86 650 M 29
VMH-2.5wk VMH 8.6e12 2.5 80 662 M 21
VMH-24wk VMH 8.6e12 24 84 S772 M 26
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Figure 2.4. Representative images (100x mag.) of coronal-aspect hypothalamic cryosections from adult (3-month-
old) male C57BL/6 mice 2.5 weeks following a single intracranial injection containing 1013 vg/kg (viral genomes 
per kg body mass) of pscAAV9-SF1-GFP packaged in scAAV9 virus (Vigene Biosciences) to show efficacy of 
injection strategies in inducing EGFP protein expression. Injections were targeted at (a) the third ventricle (1.46 
mm posterior to bregma, 5.7 mm inferior to the top of the brain) or (b) the ventromedial nucleus of the 
hypothalamus (1.46 mm posterior to bregma, 0.39 mm lateral to the midline, 5.7 mm inferior to the top of the 
brain). The third ventricle (V3) and median eminence (ME) are included as hypothalamic landmarks. Nuclei were 
stained with DAPI in mounting media and EGFP autofluorescence was imaged on the FITC channel. 
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VMH  
 Conversely, the VMH-targeted injection yielded high EGFP expression lateral to the 
third ventricle in the area of the hypothalamus, approximately 750 µm superior to the median 
eminence (ME) (b). In the VMH-targeted injection strategy, EGFP expression was present at 
the injection site in an ovoid area but also projected superiorly towards the trephination site, 
following the path that the needle would have taken. This strip of EGFP expression continued 
outside the hypothalamus and halfway to the dentate gyrus (Figure 2.5). Other areas of the 
brain were EGFP-negative. The path of the needle did not leave damage that was visible after 
2.5 weeks, with the exception of a 120 µm by 40 µm lesion-like area at the site of the injection. 
 The hypothalamic EGFP expression pattern observed in this study was compared with 
the coronal-aspect Allen Mouse Brain Reference Atlas (Figure 2.6 a,b). The VMH-targeted 
injection of scAAV9 virus containing EGFP plasmid (psc-AAV9-SF1-GFP) shows that the 
EGFP expressing area begins at approximately 850 µm superior to the bottom of the brain and 
extends for 750 µm (c), which does not overlap with the area outlined as the VMH in the Allen 
Mouse Brain Atlas (b).  In situ hybridization data included in the Allan Brain Atlas shows SF1 
mRNA occupies a region beginning 200 µm superior to the median eminence and extending 
for 700 µm (Figure 2.6d), which corresponds to the VMH as demarcated by the reference atlas 
(b) but does not correspond to the EGFP-expressing area that resulted from our VMH-targeted 
injection (c). 
 Micrographs reveal that the EGFP expression and DAPI staining were not co-
dependent (Figure 2.7). In representative micrographs, EGFP expression occurred in the 
cytoplasm (solid arrows) around nuclei and extended out in thin projections of variable length 
(open arrows), with some over 100 µm long (Figure 2.7a,b,c). Panel (d) shows multiple 
adjacent EGFP-positive filaments in parallel. 
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Figure 2.5. Representative twelve-image (100x mag. each) stitch taken on the FITC channel of a coronal-aspect 
whole brain cryosection from a male C57BL/6 mouse 2.5 weeks following a single intracranial injection 
containing 1013 vg/kg (viral genomes per kg body mass) of pscAAV9-SF1-GFP packaged in AAV9 virus (Vigene 
Biosciences) to show anatomical distribution of autofluorescent EGFP expression and evaluate injection 
accuracy. The dentate gyrus (DG), hypothalamus (H), and third ventricle (V3) are outlined as anatomical 
landmarks. The injection was targeted at the ventromedial nucleus of the hypothalamus (1.46 mm posterior to 
bregma, 0.39 mm lateral to the midline, 5.7 mm inferior to the top of the brain). 
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Figure 2.6. Panels showing coronal aspect of brain sections from male C57BL/6 mice to evaluate specificity and 
efficacy of EGFP expression. Image 72 (a) was taken from the Allen Mouse Brain Reference Atlas (coronal 
aspect) and included for spatial context then enlarged to show hypothalamic nuclei (b), coloured red. The 
corresponding brain section area (c) from an adult male mouse 2.5 weeks following a VMH-targeted injection of 
scAAV9 virus containing pscAAV-SF1-GFP plasmid at a concentration of 1013 vg/kg (viral genomes per kg body 
mass) shows the distribution of plasmid-encoded EGFP expression. Hypothalamic anatomical landmarks include 
the dorsomedial nucleus (DMH), ventromedial nucleus (VMH) and third ventricle (V3). Nuclei were stained with 
DAPI in the mounting media and EGFP was detected through autofluorescence on the FITC channel. Image 24 
(d) was taken from Allen Mouse Brain ISH Atlas for the nuclear receptor (Nr5a1), aka SF1. This image shows 
the corresponding area stained with an in situ antisense RNA probe and was included to compare the anatomical 
area of EGFP expression following intracranial injection (c) to wild-type SF1 expression in the hypothalamus (d). 
Images (a) and (d) collected from the following URL with free, open access permission © Allen Institute. 
© [2004] Allen Institute for Brain Science. Allen Mouse Brain ISH Atlas, Coronal. Available from: 
https://mouse.brain-map.org/search/index. 
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Figure 2.7. Representative images of DAPI-stained hypothalamic coronal-aspect cryosections from male 
C57BL/6 mice 2.5 weeks following a single intracranial injection containing 1013 vg/kg (viral genomes per kg 
body mass) of pscAAV9-SF1-GFP packaged in AAV9 virus (Vigene Biosciences) to show cellular localization 
of EGFP expression and cell morphology of EGFP-positive cells. EGFP-positive cell bodies and indicated solid 
arrowheads and their EGFP positive projections are indicated by open arrowheads. Nuclei were stained with DAPI 
in mounting media and EGFP was detected through autofluorescence on the FITC channel. Field of view indicated 
for each micrograph, which were taken at 400x (a,b,c) or 100x magnification (d). 
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2.4 DISCUSSION 
 The results presented in this Chapter are an essential step towards the generation of a 
transgenic animal expressing PACAP in the VMH on a PACAP-null background to study the 
effect of PACAP in the VMH on the regulation of thermogenesis. This work contributes to the 
validation of using an AAV9 vector expressing the VMH-specific SF1 promotor in 
combination with VMH-targeted injection. The control virus expressing EGFP (psc-AAV9-
SF1-GFP) is an excellent tool to characterize the efficacy and distribution of the viral genome 
in the host tissue, as EGFP can be visualized without an additional step of antibody chemistry. 
This would be much more difficult to do with PACAP, which is not autofluorescent and would 
thus require the development of an in situ hybridization protocol to detect mRNA or antibody-
based approach to detect the protein. PACAP is part of the glucagon/secretin superfamily of 
proteins and therefore shares sequence and structural similarity with a number of other 
proteins, making the development of PACAP-specific probes and antibodies difficult. If the 
AAV9 vector and SF1 promoter cause a very high level of protein expression, there is also the 
possibility of off-target effects, providing another important reason to first test expression 
patterns of AAV9 with EGFP, which does not have bioactive properties in mammalian cells. 
Thus, the development and characterization of the control virus is described in this Chapter to 
guide future stereotaxic injections, ensuring that the stereotaxic intracerebral injection 
technique, viral vector, and plasmid are all optimized before implementing the PACAP-
expressing virus. 
 The first major success provided here is that the virus and plasmid we developed were 
effective in gaining access to the host cells, introducing their plasmid pscAAV-SF1-GFP, and 
that the plasmid EGFP gene was successfully translated into functional protein by the host 
cells. Of the two strategies presented here, injection of AAV9-SF1-GFP directly into the 
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hypothalamic nucleus was more effective in inducing the desired cellular infiltration by the 
virus and expression of EGFP by host cell machinery. The ICV injection strategy used to 
deliver AAV9-SF1-GFP in this study was not successful in inducing detectable EGFP 
expression in the hypothalamus, or any other part of the brain (Figure 2.4a), while the VMH-
targeted strategy was able to induce high levels of EGFP expression in an area approximately 
equal to the size of the VMH (Figure 2.4b). These preliminary observations suggest that 
hypothalamic nucleus injections are superior when using a small injection volume (0.8-1 µL). 
The lack of EGFP expression seen in the brain sections from mice with ICV injections of 
AAV9-SF1-GFP is likely due to the large dilution factor provided by the cerebrospinal fluid 
in the third and lateral ventricles, which are connected and may have caused the virus to 
disperse so thinly that few (if any) cells of the hypothalamus were successfully infected. The 
total volume of the ventricles in the C57BL/6 mouse brain is 50 µL160 and thus the virus may 
have been diluted by up to 50x in the ICV-targeted injection strategy. 
 A zero dead volume needle and syringe were specifically used in this study to prevent 
leaking and give as localized delivery as possible. The needle was also left in place for 5 min 
following the injection to allow the injected fluid to disperse. Despite this, significant EGFP 
expression was detected along the track of the needle (Figure 2.5), suggesting that there was 
some leakage of the virus as the needle entered the brain or that injected fluid followed the 
needle as it was retracted. Future injections should increase the amount of time that the needle 
is left in place at the injection site post-injection from 5 to 10 min, and the withdrawal should 
be performed over 5min instead of 1min to discourage spreading injected fluid away from the 
injection site. 
 In comparison to the Allen Mouse Brain Reference Atlas161 in Figure 2.6 (a) and (b), 
the EGFP expression in the hypothalamus (c) was mostly outside of the VMH’s area, and thus 
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occurred largely within the area of the DMH, suggesting that this injection was proximately 
250 µm anatomically superior to the target location of the VMH. Comparing this area to the 
expression of SF1 nuclear receptor reveals that the EGFP expression (c) is also outside of the 
SF1-positive area (d), suggesting that the SF1 promoter is not functioning as specifically as 
expected. This could be due to SF1 promoter leakiness, meaning that it promotes expression 
in the absence of its inducer. Most promoters are leaky to some degree162. While this seems 
unlikely given the very low abundance of SF1 elsewhere in the brain, promoter leakiness 
increases at very high plasmid concentrations163. It should also be taken into consideration that 
the CMV promoter may still be present in some copies of the plasmid, though this would be 
surprising since the pGEM-SF1 plasmid was sequenced157 before being sent to Vigene. 
Therefore, the most probable explanation for SF1-promoter-driven EGFP expression outside 
of SF1-expressing tissue of the VMH is the very high local concentration of plasmid causing 
excessive leakiness of the promoter. 
 A closer look at cellular morphology and localization shows that EGFP expression is 
not confined to the area surrounding the cellular nuclei (Figure 2.7a-d), and thus the protein 
persists long enough to be actively transported or diffuse throughout the cell, including along 
cell projections (d). Since no neuronal marker was used in this study, it is difficult to decisively 
conclude which cell types are expressing EGFP. AAV9 vectors are capable of infecting both 
glial cells and neurons with relatively comparable efficiency (~50% in vitro expression of 
EGFP driven by CMV promoter)141. However, some preliminary observations of EGFP-
positive cell morphology presented here suggest that at least some glial cells and some neurons 
are EFGP-positive. The indicated cells in panels (a) and (b) may show glial cells since the 
projections are relatively short (Figure 2.7). Conversely, panels (c) and (d) likely show neurons 
based on the cellular projections, which are many times the length of the cell body. The 
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organized nature of the EGFP-expressing projections in panel (d) is suggestive that these are 
axons of neurons. From these data it is highly probable that at least some neurons are 
expressing EGFP. One limitation of this study is that there were no neuronal markers included 
in the histological analysis, prohibiting strong conclusions about the type and number of cells 
that were EGFP-positive.  
 The data reported here show promising evidence that the EGFP plasmid will be a useful 
tool to study the potency and specificity of gene expression driven by the SF1 promoter, but a 
number of important experiments must be performed to confidently understand the functioning 
of this genetic tool before strong conclusions can be made. Below I have outlined some 
suggested experiments that aim to improve the functionality of this technique. 
 
Future directions 
 To achieve the desired localization and specificity of expression, the viral titre should 
be reduced. Further, the injection depth should be increased from 5.7 mm to 5.725 mm to 
ensure that the virus is directly introduced to the VMH since the data presented here show that 
a 5.7 mm injection depth leads to an injection 250 µm superior to the VMH, corresponding to 
the DMH. From the micrograph in Figure 2.6c, it is tempting to suggest that perhaps the 
injections should also be targeted slightly more lateral, but due to the lateral distortion 
introduced during the slide mounting process, it is challenging to make conclusions about the 
lateral accuracy of the injection performed here. 
 Once the location of the injection is confirmed to be in the VMH, and off-target 
expression has been reduced as much as possible through reduced titre, it will be essential to 
conclusively show whether neurons are EGFP-positive, potentially by using a neuron-specific 
antibody such as Abcam’s Anti-Neurofilament heavy polypeptide antibody (Cat. No. ab8135). 
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This antibody has been shown to be effective in PFA-fixed mouse neurons164 and is selective 
for neurons over glial and other contaminating cell types. Microscopic analysis could then be 
used to determine colocalization EGFP (green) and neuropeptide heavy chain (red) to confirm 
neuronal expression of EGFP with a high degree of confidence. 
 The inclusion of the SF1 promoter in the plasmid was an important step in trying to 
prevent off-target vector-derived protein expression. To ensure that the promoter is effective 
in targeting SF1 neurons, an anti-SF-1 antibody such as the rabbit anti-NR5A1 Polyclonal 
Primary Antibody (MyBioSource cat. No. MBS9205805). This antibody has been shown 
independently by a separate research group to be effective in histological analysis of SF1 in 
mouse cell lines165. The injection and slide preparation could be performed similar to the 
methods detailed in the above paragraph, followed by counterstaining with anti-SF1 antibody 
and a fluorophore-bearing conjugated secondary antibody. Ideally, the fluorophore on the 
secondary antibody would be orange (i.e. BD Horizon™ PE-CF594) to allow for the potential 
of using it in conjunction with the neuronal marker described above. This experiment would 
provide a qualitative measure of off-target EGFP expression. 
 A quantitative measure of the efficacy of the promoter would require counting the 
percentage of SF1-positive and SF-negative cells that express EGFP. This could be 
accomplished by microscopy or flow cytometry. The manufacturer of the anti-SF1 antibody 
above has provided results showing that it is suitable for use in flow cytometry as well. Thus, 
the hypothalamus could be excised from the brain of a euthanized VMH-injected mouse either 
before or after fixation166, then single neurons could be isolated from the hypothalamus tissue 
by digestion. Given the small amount of starting material, it would probably be best to perform 
the neuron isolation before the fixation step since digestion of unfixed tissues tends to give 
higher yields of intact cells. DAPI and SF-1 staining could then be performed, followed by 
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quantitative analysis by flow cytometry. Flow cytometry analysis of mouse neurons has been 
performed previously167 on neurons isolated using the Neural Tissue Dissociation Kit (P) 
(Miltenyi Biotec) and thus would be a good place to start. Intact, single neurons could be 
identified using DAPI fluorescence and standard singlet gating, and in the same analysis 
experiment, cells could be separated based on fluorescence on the FITC and PE-CF594 
channels to identify four populations of cells: SF1(-)/EGFP(-), SF1(+)/EGFP(-), SF1(-
)/EGFP(+), and SF1(+)/EGFP(+). A high proportion of SF1(+)/EGFP(+) neurons would 
indicate specificity of the SF1 promoter. 
 
2.5 CONCLUSION 
 In conclusion, significant progress has been made in the development of a method for 
the stereotaxic intracerebral injection of AAV9 viral particles containing pscAAV9-SF1-GFP 
plasmid. The results show that the injection was within 250 µm of the target site, the AAV9 
successfully incorporated its genome into the host brain tissue, injected mice were free of 
malaise, and that the pscAAV9-SF1-GFP plasmid EGFP gene was successfully expressed by 
host cellular machinery in vivo. Improvements to this protocol will include site targeting based 
on coordinates optimized for our mice, reduced non-VMH neuron expression of EGFP, and 
better characterization of EGFP expressing cell types. The resulting method will provide 
evidence for an effective gene delivery strategy and will support the implementation of a virus 
carrying the PACAP gene driven by the SF-1 promoter. This study will allow us to characterize 
the contribution of VMH-derived PACAP to energy regulation including adaptive 
thermogenesis and will therefore provide a more comprehensive understanding of central body 
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mass regulation that will contribute to efficacious and safe treatment of obesity as new 
therapeutics are developed. 
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Chapter Three: Investigating a Role for PACAP in Adipocyte-
Mediated Activation of Thermogenesis  
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Preface  
Content from this Chapter was, in part, published previously168. 
 
3.1 INTRODUCTION 
 Adipose tissue is central to the regulation of energy metabolism. This role is highlighted 
by the debilitating effects of perturbations to adipose tissue functioning seen in metabolic 
disease. Despite this, adipose tissue biology is not well represented in the literature. In recent 
years this has begun to change, leading to a better understanding of adipose tissue physiology 
and the identification of potential therapeutic targets for the treatment of body mass-related 
metabolic disease. The pathology of obese adipose tissue has been characterized, revealing the 
importance of both physical and metabolic processes in maintaining adipose tissue 
function19,35,38,51,68. These include limits of physical remodeling of adipose tissue through 
hyperplasia and hypertrophy169,170, and decreased adipocyte lipid turnover47,53. Finally, a long-
known process called adaptive thermogenesis is now being rigorously examined as a 
mechanism to burn lipids in adipose tissue and thus may be a promising therapeutic target to 
increase energy expenditure171,172. By studying the mechanisms by which adipose tissue 
maintains energy balance, or how cellular mechanisms can malfunction in adipose tissue, we 
hope to enhance the understanding of the pathophysiology of obesity. 
 Accumulation of lipid in adipose tissues past their normal range in obesity drives a 
number of such pathological consequences. This defines an upper limit of storage capacity that 
when exceeded results in metabolic decompensation as observed in the Metabolic Syndrome. 
Exceeded adipose capacity manifests as excessive adipocyte hypertrophy and results in 
pathophysiological changes in lipid metabolism within the adipose tissue and negative effects 
on the endocrine function of the tissue31,169. In obese individuals, decreasing adipose lipid 
content and increasing energy expenditure would improve energy balance, outcomes that could 
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be simultaneously achieved through induction of adaptive thermogenesis. Thus, renewed 
interest in the search for novel strategies to induce adaptive thermogenesis has focused on the 
physiology of a specialized adipose tissue called brown adipose tissue (BAT). This energy-
burning fat produces heat using lipids in response to cold or overnutrition. Augmenting BAT 
function or programming white adipose tissue (WAT) to act like BAT would shift the overall 
adipose tissue function from energy storing organs into energy burning ones. As proof of 
concept, remarkable improvements in glucose homeostasis have been shown simply through 
the implantation of exogenous BAT into mice173. The understanding of the biochemical and 
physiological regulation of adaptive thermogenesis has increased greatly since its identification 
as a potential therapeutic target.  
 
Adipose tissues and their capacity for thermogenesis  
 Adaptive thermogenesis is regulated by the secretion of norepinephrine from 
sympathetic nerve terminals that synapse onto thermogenic adipocytes. Brown adipocytes are 
very responsive to β-adrenergic stimulation due to their high membrane concentrations of beta-
3 adrenergic receptor (β3-AR)64,174,175. Brown adipocytes have a high density of mitochondria 
that facilitate the high rates of β-oxidation of fatty acids required for heat production via 
uncoupling protein 1 (UCP1)176-178,179. Indeed, the abundance of mitochondria is what makes 
BAT brown in colour. The stored lipid in BAT is used to fuel thermogenesis and is reduced in 
cold-acclimated BAT from the interscapular depot180,181. BAT has also been shown to undergo 
hyperplasia with exposure to cold176 to increase thermogenic capacity of the tissue and meet 
thermogenic demands to maintain homeostasis.  
 Not all adipose tissues contain thermogenic adipocytes. Energy expenditure can be 
controlled differentially in each adipose depot by the selective stimulation of sympathetic 
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output tracts to one or more adipose depots. The functional significance of β-adrenergic 
stimulation depends on the intracellular machinery at the target adipocyte, and thus the 
physiological response differs by depot. For example, β3-AR stimulation of the thermogenic 
BAT depot will stimulate both lipolysis and thermogenesis, while this same signal in most 
WAT results only in an increase in mobilization of lipids with no accompanying increase in 
thermogenic recruitment32. 
 White adipose tissues can be broadly divided into two groups with respect to 
thermogenesis. While classical white adipocytes do not express significant amounts of UCP1 
to allow for heat production, some white adipose tissues possess the ability to “brown” by 
developing cells with significant UCP1 expression. In mice, the inguinal white adipose tissue 
(ingWAT) is a subcutaneous depot known to undergo this process182. If housed at 
thermoneutrality (30°C), mice need not perform thermogenesis to maintain euthermia. In this 
state, the ingWAT adipocytes are uniform in size, having a large single lipid droplet, few 
mitochondria relative to BAT or muscle, and low expression of UCP172. Conversely, when 
mice are housed at 4°C, high rates of thermogenesis are required to maintain an internal 
temperature of 37°C. This thermogenic requirement drives remodeling of subcutaneous 
adipose tissues such as ingWAT including the appearance of thermogenic adipocytes178. These 
adipocytes are not true brown adipocytes, since they are derived from a different lineage of 
progenitors and express lower levels of UCP1 compared to brown adipocytes. Due to their 
intermediary morphology between brown and white adipocytes, they have been called “beige” 
or brown-in-white “brite” adipocytes owing to their anatomical location. Understanding the 
mechanisms of browning in white adipose tissue depots may have therapeutic potential to 
enhance energy expenditure in obesity63,70,172,183,184. 
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 Classical murine visceral white adipose such as gonadal adipose tissue (gWAT) does 
not undergo adaptive thermogenesis in response to cold exposure, at least in part due to genetic 
inhibition of browning, which when experimentally removed, allows browning in gWAT185. 
In response to cold exposure the lipid stores of this depot are depleted, but this does not 
correlate to an increase in UCP1 expression.  
 
Sympathetic activation of thermogenesis and genetic control 
 Thermogenesis is inseparable from β-oxidation of fatty acids186,187 but glycolysis is 
dispensable188 for thermogenesis, despite the fact that glycolysis is capable of producing 
reducing equivalents for the electron transport chain. Exogenous free fatty acid (oleate) 
administration alone can increase thermogenesis as measured by oxygen consumption in 
primary brown adipocytes independent of β-adrenergic stimulation189. As such, β3-ARs are 
densely expressed on thermogenic adipocytes and their activation increases lipolysis, 
thermogenesis, and genes controlling expression of UCP1. In BAT, protein kinase A (PKA) 
activation leads to the phosphorylation of cAMP response element-binding protein (CREBP), 
which is an essential transcription factor driving thermogenic capacity of adipocytes. CREBP 
drives the expression of another transcription factor peroxisome proliferator-activated receptor 
gamma (PPAR-g), ultimately resulting in increased UCP1190 expression. In contrast, cold-
exposed WAT does not have the same increases in genes known to drive UCP1 expression, 
providing a potential mechanism to explain the lack of browning of certain white adipose 
tissues191. Thermogenic vs non-thermogenic adipocyte status is maintained by differences in 
transcriptional control50,192-194, epigenetic modifications192, and sympathetic innervation32,195. 
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Thus, while sympathetic stimulation of BAT and some WAT drives browning, some WAT 
depots are destined to be non-thermogenic.  
 
Endocrine control of thermogenesis  
 As discussed, sympathetic stimulation of thermogenic adipocytes by norepinephrine is 
the key regulator of thermogenesis. Other endocrine factors can increase the thermogenic 
capacity of brown adipocytes or increase the receptivity of the adipocytes to adrenergic 
stimulation by the sympathetic nervous system. One such factor is bone morphogenic protein-
8b (BMP8B), which is expressed in BAT. Treatment with this protein increases the 
differentiation and thermogenic response of brown adipocytes to norepinephrine196. BMP8B is 
also implicated in central regulation of thermogenesis, being expressed in the ventromedial 
nucleus (VMH) of the hypothalamus. Mice lacking BMP8B have decreased sympathetic output 
to BAT196 and intracerebroventricular (ICV) injection of BMP8B increases the rate of BAT 
thermogenesis and significantly enhances thermogenic gene expression in BAT196. Another 
autocrine/paracrine factor that has been shown to modulate thermogenesis is fibroblast growth 
factor-21 (FGF21), which upregulated in BAT of mice during cold stress197. Treatment of 
brown or white adipose tissues with FGF-21 increases the expression of thermogenic genes198, 
including UCP1. Vascular endothelial growth factor A (VEGFA) is secreted by BAT to 
increase vascularization and increase the expression of UCP1 with cold stress199. Coupling of 
these processes by VEGFA results in increased thermogenesis in BAT, as well as increased 
export of heat form this tissue via the blood. Ablation of VEGFA in mice impairs the cold 
acclimation response200. Another potent activator of the thermogenic program is the thyroid 
gland-derived hormone, thyroxine (also known as tetraiodothyronine), which reaches the BAT 
through the bloodstream and seems to be required for the full induction of UCP1 in this tissue 
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in the face of cold exposure201. These findings and others have increased interest in 
understanding the endocrine regulation of BAT in the hopes of specifically targeting 
thermogenic activation for therapeutic use.  
 In this chapter we will investigate the possibility that pituitary adenylate cyclase-
activating polypeptide (PACAP) may act in an endocrine manner to stimulate thermogenesis 
or increase the capacity of brown adipocytes to perform thermogenesis. Peripheral expression 
of PACAP is confined to immune cells, gonads and pre-ganglionic sympathetic and 
parasympathetic neurons, including those innervating exocrine and endocrine glands such as 
the pancreas202, genitourinary tract, and the adrenal medulla, where it is the primary 
neurotransmitter. The expression and significance of PACAP and its receptors in adipose tissue 
depots of mice or humans has not yet been fully explored. In mice, only scattered reports exist 
of PAC1R in rat adipocyte cell lines and VPAC2 expression in cultured primary rat 
adipocytes203. In humans, only a single report of genetic expression of PAC1R in adipose tissue 
exists, and this report neglects to report the depot from which the cDNA were isolated204. No 
evidence of PAC1R expression in brown adipocytes has yet been reported.  
 The possibility that PACAP may be present in the neurons innervating the adipose 
tissue is supported by the fact that PACAP is expressed in nerve terminals innervating other 
important energy regulatory functions, such as the adrenal medulla. PACAP is produced and 
secreted by the preganglionic sympathetic nerves of the adrenomedullary synapse88. It is 
important to note, however that the adipose tissues are innervated by postganglionic neurons, 
and thus our expression data will not detect PACAP if it is acting further upstream, at the 
preganglionic synapse.  
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We hypothesize that PACAP acts directly at the adipocyte to regulate thermogenesis in BAT. 
 The objectives of this chapter are as follows: 
AIM 1: Produce a robust mouse model of maximal activation of thermogenesis and 
 characterize genetic changes in PACAP and its receptors in response to cold 
 acclimation.  
AIM 2: Determine whether PACAP or its receptors are expressed specifically by mouse 
adipocytes. 
AIM 3: To assess the functional significance of PACAP binding to PAC1R at the adipocyte 
 with respect to thermogenesis and lipolysis in vitro. 
This work will increase our understanding of the endocrine regulation of energy metabolism 
in adipose tissues. These insights will help inform treatment of obesity and better management 
of the comorbidities associated with the disease, many of which are a consequence of adipose 
tissue pathophysiology. 
 
3.2 MATERIALS AND METHODS 
Animals 
 Adult (12-week-old), male, wild-type C57BL/6 mice were obtained from Charles River 
Laboratories (Sherbrooke, QC, Canada) and housed two per cage with sterile corncob bedding 
on a 12-h light to 12-h dark cycle (lights on 0700–1900 h). Water and standard rodent chow 
diet were freely available (LabDiet 5001, LabDiet, Inc., Brentwood, Leduc, AB, Canada; 
metabolizable energy 3.02 kcal/g). For PACAP receptor expression analysis, mice 
(n = 8/treatment) were housed at thermoneutrality (30 °C) (Solace Zone, Alternative design, 
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Siloam Springs, AR, USA) or cold (4 °C) conditions for 3.5 weeks to achieve full cold 
acclimation64. Mice utilized for cell culture were housed at 24°C until 10 weeks of age. Body 
mass (g) for all mice was measured twice weekly to detect potential declines in mouse health. 
Measurements of fat, fluid, and lean mass (g) were collected weekly by time-domain nuclear 
magnetic resonance (TD-NMR) using a minispec LF50 (Bruker, Billerica, MA, USA). Mice 
were unrestrained during the 2-min measurement period. Care and treatment of mice was in 
accordance with the guidelines of the Canadian Council on Animal Care, and protocols for the 
study were approved by the University of Northern British Columbia’s Animal Care and Use 
Committee. 
 
Postmortem Analysis and Tissue Processing  
 Non-fasted mice were anesthetized with isoflurane and sacrificed by cardiac puncture 
followed by cervical dislocation. Interscapular brown adipose tissue (iBAT), inguinal 
subcutaneous white adipose tissue (ingWAT), and gonadal white adipose tissue (gWAT) were 
collected by dissection, weighed and flash-frozen in liquid nitrogen and stored at −80 °C for 
RNA analysis or fixed in 10% formalin then stored in 70% ethanol for histological analysis. 
These adipose tissue depots were selected as they represent the classic thermogenic brown fat 
(iBAT), an inducible thermogenic white fat depot that contains beige adipocytes (ingWAT), 
and a non-thermogenic intraperitoneal white fat depot (gWAT), thus encompassing the 
physiologically distinct roles of fat with respect to thermogenesis 205. 
 
Histological Analysis of Adipose Tissue 
 Adipose tissues (iBAT, ingWAT and gWAT) were fixed in 10% formalin for 36 h and 
then stored in 70% ethanol for 2-3 months. Samples were embedded in paraffin, sectioned (5 
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μm) and stained with hematoxylin and eosin (Wax-it Histological Services, Vancouver, BC, 
Canada). Images were captured, processed, and measured using cellSens Dimension software 
controlling a BX61 microscope and attached DP72 camera (Olympus Richmond Hill, ON, 
Canada).  
 For iBAT, ten regions of interest (ROI) at 20X magnification were examined across 
four sections for each tissue from each mouse (n = 4 per treatment). Slides with visibly 
damaged adipocytes or with contaminating epithelial tissue were excluded from image 
analysis. Micrographs were processed manually by selecting and deleting areas with 
contaminating tissue that was not representative of adipocyte morphology, such as blood 
vessels, erythrocytes, and macrophages and therefore were mathematically excluded in 
downstream analysis of area calculations. Photographs of the ROIs were captured, converted 
to grayscale and contrast was digitally maximized. White areas in these micrographs represent 
lipid droplets, which appear transparent-white due to lack of staining of these regions, and 
coloured areas represent cytoplasm (pink) or nuclei (purple). The images were computationally 
binarized to black and white. Non-lipid area was calculated by cellSens software as black areas 
in the ROI, and this area was then subtracted from the total area to give the lipid area (white 
area), which was then divided by total area to give lipid area as a percentage of the total ROI 
area.  
 To assess cell size, the number of cells per ROI were determined by manually counting 
the number of nuclei per ROI. Each ROI was split into four panels and the panels counted 
individually, then summed to increase accuracy of the counts. To mitigate bias, all photographs 
and calculations were performed by the same individual who was blind to the treatment of each 
sample. 
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 For ingWAT and gWAT, histological sections were prepared as described above and 
representative micrographs (20x) taken to assess the anatomical changes associated with cold 
acclimation. 
Adipose Tissue Fractionation 
 Adipose tissue was fractionated into the pelleted stromal vascular fraction (SVF) and 
the buoyant mature adipocyte fraction for gene expression analysis in each fraction. Non-
fasted, male C57BL/6 mice (n = 6) were sacrificed and BAT, ingWAT and gWAT adipose 
tissue depots were dissected and trimmed on ice visually aided by an SZX7 Olympus dissecting 
microscope to remove contaminating material: muscle and white fat from the iBAT, lymph 
nodes from the ingWAT, and reproductive tissues from the gWAT. Adipose tissues from six 
mice were pooled by depot and minced into 1–2 mm pieces and digested in 10 mL Hank’s 
Balanced Salt Solution with 2% Bovine Serum Albumin (Sigma Aldrich, St. Louis, MO, USA), 
150 U/mL Type II Collagenase (Sigma Aldrich), and 5 mM CaCl2 at 37°C, at 200 rpm in a 
two-directional shaker for 1h. Tubes were inverted every 15min to ensure even distribution of 
the collagenase. Tissue slurries were strained (300μm) and fractionated by centrifugation at 
350 rcf for 5 min at 4 °C. Buoyant cells were collected carefully from the floating layer, 
supernatant was discarded, and the pelleted SVF was collected. The mature fraction was 
washed twice with phosphate-buffered saline (PBS). The collected fractions were flash-frozen 
in liquid nitrogen and stored at −80 °C. 
 
Primary Tissue Culture  
 To assess PACAP receptor expression in pre-adipocytes or mature adipocytes without 
contaminating vasculature, neural innervation or immune cells, adipocytes were grown in 
primary culture, and half the wells were collected at confluence while the other half were 
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differentiated to become mature adipocytes before being collected. Fourteen-week-old, male 
C57BL/6 mice (n = 24) were sacrificed and adipose tissues collected by dissection, digested 
and fractionated as above. Debris and undigested material were removed using a tissue strainer 
(100 μm) and red blood cells removed using Red Cell Lysis Buffer (Sigma Aldrich, St. Louis, 
MO, USA) according to the manufacturer’s protocol. The cells were washed by centrifugation 
and resuspension in Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture F-12 Ham 
(DMEM/F12) three times, with the mature layer being discarded following the first 
centrifugation, then the resuspended SVF containing pre-adipocytes was plated and cultured at 
37 °C, 5% CO2 in a 6-well plate until confluent. Growth media contained DMEM/F12, 0.01 M 
HEPES buffer, 10% fetal bovine serum (FBS), and 1% v/v antibiotic (penicillin/streptomycin) 
(Sigma Aldrich). One day post-confluence, half the wells for each tissue type were collected 
for RNA extraction (n = 3) and the other half (n = 3) were differentiated for 6 days in media 
containing 1.5 nM tetraiodothyronine, 4 nM insulin, and 126 μM/mL sodium L-ascorbate. Full 
differentiation was assessed in primary adipocytes by the presence of large lipid droplets in 
70% of cells. For primary brown adipocyte cultures, maturation was confirmed post hoc by 
measuring induction of UCP1 mRNA expression.  
 
RNA Extraction and cDNA Generation  
 All equipment and reagents were acquired from Thermo Fisher Scientific (Waltham, 
MA, USA) unless otherwise stated. Samples (n = 8 per treatment) of iBAT, ingWAT, and 
gWAT from the acclimated mice (thermoneutrality (30 °C) or cold (4 °C)) were homogenized 
completely using a PowerGen 125 power homogenizer according to tissue and treatment type. 
Cells were lysed, RNA extracted and purified using Trizol Reagent and subsequently ethanol 
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precipitated as per the manufacturer’s protocol with the following modifications: the extra 
centrifugation step for high fat samples was utilized and RNA precipitation was conducted for 
1h at −20 °C, then 10 min at −80 °C. RNA purity was assessed by spectrophotometry 
(NanoDrop 1000). Integrity of the RNA was assessed by the quality of 18S and 28S bands on 
a native 1.5% agarose gel stained with 0.5% ethidium bromide. DNA contamination was 
removed by treating extracted RNA with TURBO-DNase as per the manufacturer’s protocol. 
RNA was reverse transcribed to cDNA using iScript Reverse Transcription Supermix for RT-
qPCR (Bio-Rad; Hercules, CA, USA) containing a blend of oligo(dT) and random primers to 
prevent bias during cDNA synthesis. Additionally, no-template and no-RT negative controls 
were performed to test for contaminating genomic DNA. RNA extractions from primary cell 
culture and fat fractionation experiments were performed using RLT lysis buffer and RNeasy 
Mini and RNeasy Micro kits, respectively (QIAGEN, Hilden, Germany). Furthermore, RNA 
integrity from fat fractions was assessed using the Experion (Bio-Rad) automated 
electrophoresis system using RNA StdSens kits according to the manufacturer’s instructions. 
 
Real-time quantitative PCR (qPCR) 
 Melt curves were visually assessed and amplification efficiency was determined for all 
primers in Table 3.1 (Integrated DNA technologies (IDT), Coralville, CA, USA) to detect non-
specific products and primer-dimer formation, respectively. Homogeneity of reference gene 
expression was indicated by an M-value lower than 0.5 for each primer pair (geNorm, qBase+ 
software, Biogazelle, Zwijnaarde, Belgium). Primers and PrimeTime (IDT) hydrolysis probes 
were designed using the NCBI online PrimerBLAST tool. SYBR Green chemistry (SYBR 
Green Supermix for iQ5, Bio-Rad) was used to measure mRNA expression of UCP1, β3-AR, 
homeobox protein Hox-C9 (HOXC9), hormone-sensitive (HSL), PAC1R, VPAC1, and VIP. 
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Table 3.1. Primer and probe sequences used for real-time quantitative PCR. All primers developed using the 
National Center for Biotechnology (NCBI) online Primer Blast tool with the Accession numbers provided. 
 
 
 
  
Target Genes NCBI Accession # Forward Primer (5'-3') Reverse Primer (5'-3') Annealing T (ºC)
HOXC9 NM_008272.3 GCAGCAAGCACAAAGAGGA CGTCTGGTACTTGGTGTAGGG 58
HSL NM_010719.5 GGAGCACTACAAACGCAACGA TCGGCCACCGGTAAAGAG 55
PAC1R NM_007407.4 TTGATGACTATGAGCCCGAGT ACAAGATGACCATGGCAGTG 57
PACAP NM_009625.3 ATCCAGCGGACAGGAGAGAT TCCGAGTGGCGTTTGGTAAG 55
UCP1 NM_007407.4 CCTGGCAGATATCATCAC TCACCTTGGATCTGAAGG 52
VIP NM_011702.3 CAGGAACCGGGAACAGACT TATCAGGAATGCCAGGAACT 57
VPAC1 NM_011703.4 AAGTCATTGTAGAGGCAGAT AATATGTCAAGACGGAATCAG 59
VPAC2 NM_009511.2 AGAGCCATCTCTGTGCTGGTCAA AGGTAGGCCAGGAAGCAC 57
β3-AR NM_013462.3 CAACCCGGTCATCTACTG ACCGTAGCTACACAGAAG 50
VPAC2 NM_009511.2 63
PACAP NM_009625.3 56FAM/TCGCCCACG/ZEN/AAATCCTTAACGAAGCCTATCGAA/3IABkFQ 62
β-actin NM_013462.3 GCTCTGGCTCCTAGCACCAT GCCACCGATCCACACAGAGT 55
GAPDH NM_001289726.1 TGCACCACCAACTGCTTAG GGATGCAGGGATGATGTTC 55
RPL19 NM_009078.2 CCATGAGTATGCTCAGGCTACAG CTGATCTGCTGACGGGAGTTG 57.5
TBP NM_013684.3 CACCAATGACTCCTATGA CCAAGATTCACGGTAGATA 53
18S NR_003278.3 CGGCTACCACATCCAAGGAA GCTGGAATTACCGCGGCT 55
56FAM/CAGGTAGAG/ZEN/ACCCTCCACCAGAAGCCAGTAG/3IABkFQ 
Hydrolysis Probes (5'-3')
Reference Genes 
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 Amplification conditions were as follows: 95 °C/180 s, 95 °C/10 s, and then (annealing 
T)/30 s (repeat 40 times) (annealing temperatures in Table 3.1). Melt curves were performed 
by 55 °C/10 s + 0.5 °C per repeat up to 95 °C to ensure that a single peak, corresponding to a 
single qPCR product, was obtained for each reaction. mRNA expression for each gene was 
analyzed using the comparative CT method. MIQE guidelines206 were considered in the design 
and optimization of primers and probes, as well as the determination of relative expression for 
all of the above genes.  
 
RNA sequencing 
 To determine which PAC1R splice variants were most prevalent in iBAT samples of 
thermoneutral and cold-acclimated mice, mRNA (1 μg) was sequenced at a depth of 25 million 
paired-end reads on a NextSeq 500 sequencing system (Illumina, San Diego, CA, USA) at the 
Biomedical Research Centre (UBC, Vancouver, BC, Canada). Samples (n = 3/treatment) were 
chosen based on RNA-Quality Index values obtained from Experion electrophoresis following 
TURBO DNase treatment. cDNA libraries were prepared using the TruSeq Stranded mRNA 
Library Prep Kit and analysis of the resulting paired-end sequence data was performed in the 
BaseSpace Sequence Hub (Illumina) as follows. TopHat207 was utilized for alignment to the 
Mus musculus UCSC mm10 reference genome. Indexing and variant calls were determined 
using Strelka Variant caller208. Fragments per kilobase million (FKPM) calculation and 
differential expression, including statistical analysis, was performed using Cufflinks207.  
 Significance level was determined by use of q-value (Cufflinks), which is a p-value 
that is adjusted for false-discovery rate. 
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Lipolysis Assay in Primary Adipocytes  
 Rates of lipolysis were determined by measuring free fatty acids (n = 4) and free 
glycerol (n = 2) in tissue culture media following acute stimulation of β3-AR and/or PACAP 
receptors in differentiated primary cultures of murine adipocytes. All reagents were obtained 
from Thermo Fisher Scientific (Waltham, MA, USA) and used in accordance with the 
manufacturer’s instructions unless otherwise stated. Preadipocytes isolated from iBAT and 
ingWAT, cultured to 90% confluence, and differentiated into mature adipocytes as stated in 
the above primary culture methods. On day 5 post-confluence, cells were gently washed three 
times with 37 °C PBS to remove differentiation media containing newborn calf serum (serum 
Cat. No. N4637), which may contain hormones that stimulate lipolysis. Following washing,  
37 °C DMEM/F12 (Cat. No. 12634028) was added to each well and plates were incubated for 
4 h without media supplementation to establish a baseline state were lipolytic pathways are not 
extrinsically activated in cultured adipocytes.  
 During the stimulatory phase of the assay, a Krebs-Ringer-HEPES assay buffer (120 
mM NaCl, 5 mM KCl, 1.2 mM MgSO, 10 mM NaHCO, 1.3 mM CaCl, 1.2 mM KHPO,             
20 mM HEPES) was prepared with 0.5 mM glucose, 4% bovine serum albumin (BSA) at pH 
7.4 and supplemented with the β3-AR agonist CL316,243, which is a potent stimulant of 
lipolysis209,210 and/or mixtures of PACAP receptor agonists. All agonists and their 
concentrations can be found in Table 3.2. Maxadilan is a potent and specific agonist of 
PAC1R95, PACAP is an agonist for all three PACAP receptors (PAC1R, VPAC1 and VPAC2), 
and M65 is a potent, specific antagonist of the PAC1R receptor96. M65 was used in 
combination with PACAP to prevent stimulation of PAC1R while allowing stimulation of 
VPAC1 and VPAC2, for which specific agonists are not currently available.  
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Table 3.2. Treatment scheme for free fatty acid and glycerol quantification assay. Final concentrations of agonists 
and antagonists in the media are shown. Agonism strength is denoted by (+), antagonism strength by (-), as 
described in the literature. Reagents obtained from Thermo Fisher Scientific (Waltham, MA, USA). Phosphate 
buffered saline (PBS) was used as the diluent for all reagents.  
  
Media supplements  Receptor agonism (+) or antagonism (-) 
Reagent Concentration (µM) β3-AR  PAC1R VPAC1 VPAC2 
PBS 1X     
CL316,243 1 + + +    
Maxadilan 0.5  + + +   
PACAP 0.1  + + + + 
M65 1.5   - - -     
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Cells were incubated with supplemented media described above at 37 °C for 2 h and then 
immediately placed on ice to stop metabolic processes while assay media (300 µL) were 
collected and flash-frozen in liquid nitrogen. Media aliquots were later thawed on ice and 
diluted in Assay Buffer (1:5). Free fatty acid content in the media were quantified using a free 
fatty acid kit (Abcam, Burlingame, CA, USA) as per the manufacturer’s protocol. Fluorometric  
readings (excitation/emission = 535/587 nm) were measured using a Varioscan LUX 
Multimode Microplate Reader (Thermo). 
 
Cellular Oxygen consumption  
 To assess potential cooperativity of PACAP and adrenergic receptors in activating 
thermogenesis, in-well oxygen consumption of mature primary adipocyte cultures was 
measured using a Seahorse Analyzer (Agilent, Santa Clara, CA, USA)  after acute stimulation 
of the β3-AR and PAC1R. Male C57BL/6 mice (n = 20) were housed at the animal unit in the 
Pharmaceutical Sciences Building at UBC, Vancouver, until 14 weeks of age (Charles River, 
Sherbrooke, QC, Canada). Mice were euthanized using CO2, followed by cervical dislocation. 
ingWAT and iBAT depots were collected by dissection and preadipocytes were isolated and 
grown in primary culture as described previously, except with the following modifications: 
erythrocytes were not lysed prior to plating, and Collagenase Type I (StemCell Technologies, 
catalog # 07416) was substituted because Type II collagenase from Sigma was no longer 
available. Care and treatment of mice were in accordance with the guidelines of the Canadian 
Council on Animal Care, and protocols for the study were approved by the University of British 
Columbia’s Animal Care Committee.  
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 Following adipose tissue digestion and centrifugation, SVFs were pooled by tissue type 
(hereafter called iBAT and ingWAT) and then plated into 50 wells of a 96-well plate. Cell 
density was assessed visually three days post-plating, each well was photographed prior to the 
induction of differentiation to record plating density, and final percent maturity visually 
assessed immediately prior to the oxygen consumption assay. Two wells of iBAT adipocyte 
cultures and four wells of the ingWAT adipocyte cultures had significantly fewer mature cells 
than the other wells at the time of the assay and were therefore excluded from the analysis.  
 The purposes of each treatment group were described below. Saline was a vehicle 
control to show unmodified response to stimulation of oxygen consumption by carbonyl 
cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP). CL316,243, a β3-AR agonist, was a 
positive control for adrenergic-stimulated oxygen consumption because it is known to 
stimulate lipolysis and mitochondrial activity 174 in adipocytes. Maxadilan, a PAC1R agonist, 
was used to assess stimulation of PAC1R only. PACAP was used as a non-specific agonist to 
stimulate PAC1R, VPAC1, and VPAC2. PACAP was used in combination with M65 to 
selectively stimulate VPAC1 and VPAC2 while preventing stimulation of PAC1R.  
 To measure oxygen consumption of mitochondrial origin the Seahorse XF Mito Stress 
Kit assay (Agilent Technologies, Santa Clara, CA USA) was performed according to 
manufacturer’s instructions (Figure 3.1) with some modifications (see Table 3.2) following 
stimulation of cells with the agonists listed above. 
 The main modification of the assay was the addition of an extra injection step to 
accommodate the addition of β3-AR and/or PACAP receptor agonists prior to the addition of 
FCCP. Therefore, the assay protocol (total 1 h, 48 min) for both differentiated brown 
adipocytes and differentiated white adipocytes consisted of five phases in the following order: 
Baseline  
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Figure 3.1. Manufacturer protocol for the Agilent Seahorse Mitochondrial Stress Test kit to show expected effects 
of kit reagents on oxygen consumption in cultured adipocytes. Image created from data in this Chapter.  
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(equilibration- no injection), Phase 2- Oligomycin (2 µM), Phase 3- Experimental Agent(s) 
(Table 3.2) Phase 4- FCCP (µM) and Phase 5- Rotenone/Antimycin A (1 µM). The effect of 
four of these Phases on oxygen consumption can be seen in Figure 3.1. Each 18-min phase, 
excluding the 24-min Baseline, consisted of an injection of agonists followed by three cycles 
of the following: 3 min of automated mixing (to ensure even distribution of the experimental  
agent), 3 min measurement of in-well dissolved oxygen and pH. In the Baseline phase, no 
injection was performed and there were four cycles.  This allows the cells to equilibrate to the 
assay conditions and facilitates the establishment of baseline metabolism for comparison 
against the subsequent treatments. 
 
3.3 RESULTS 
Animal and organ morphology 
 At the start of the acclimation period, (a) overall body mass, (b) lean mass, and (c) fat 
mass were not significantly different between treatment groups (Figure 3.2). Following 
housing for 3.5 weeks at 4 °C (cold-acclimated) or 30 °C (thermoneutral), overall body mass 
and fat mass, but not lean mass, were significantly lower in the cold-acclimated group. The 
masses of the white adipose depots (ingWAT and gWAT) were significantly lower in the cold-
acclimated mice compared to the thermoneutral mice. iBAT mass did not differ significantly 
between treatments (Figure 3.2d).  
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Figure 3.2. Whole body mass, composition, and post-mortem adipose tissue mass measured over 3.5 weeks of 
cold acclimation (housing at 4 °C) in male C57BL/6 mice compared to thermoneutral-housed (30 °C) control 
mice. Body mass (a), lean mass (b), and total fat mass (c) were measured by non-invasive time-domain nuclear 
magnetic resonance (Bruker minispec LF50) (n = 8 for days 0 and 21, n = 4 for days 7 and 14). Sample size differs 
due to technical problems. Adipose depot mass (d) of interscapular brown adipose tissue (BAT) subcutaneous 
inguinal while adipose tissue (ingWAT), and visceral gonadal adipose tissue (gWAT) determined by dissection 
measured post-mortem at 3.5 weeks (n = 8). Data are expressed as mean ± SD and asterisks denote a significant 
temperature effect at α = 0.05 (30 °C vs. 4 °C). 
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Histological analysis 
 Hematoxylin and eosin stained sections of iBAT from cold-acclimated mice appeared 
visually darker and with a higher degree of adipocyte multilocularity than iBAT sections from  
thermoneutral controls (Figure 3.3a,b). Darker-staining cells with multilocular lipid droplets, 
indicative of thermogenic adipocytes, appeared in sections of cold-acclimated ingWAT (Figure 
3.4a,b) but not cold-acclimated gWAT (Figure 3.5a,b). In contrast, multilocular cells 
(thermogenic adipocytes) were not detected in ingWAT nor gWAT sections of mice kept at  
30 °C for 3.5 weeks. Analysis of iBAT sections showed decreased mean lipid area (Figure 
3.3c) and increased cell number (Figure 3.3d) in sections from cold-acclimated mice. 
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Figure 3.3. Cold acclimation of interscapular brown adipose tissue (iBAT) after 3.5 weeks of cold exposure (4 °C 
housing) in male C57BL/6 mice compared to thermoneutral-housed (30 °C) control mice. Representative bright 
field images (a and b) of Hematoxylin- and Eosin-stained sections of dissected iBAT taken at 600x magnification. 
Histological analysis of iBAT from cold-acclimated mice showing lipid area (c) as a percentage of the total region 
of interest (ROI) area and the number of brown adipocytes (d) per ROI (n = 4) as determined by nuclei count. 
Micrograph acquisition, and image processing for lipid area quantification were performed using Olympus 
CellSens software, while nuclei counts were performed manually from visual analysis of the images. Relative 
mRNA expression (e) of genes related to iBAT thermogenesis: uncoupling protein 1 (UCP1), b3 adrenergic 
receptor (b3-AR), and hormone-sensitive lipase (HSL) (n = 8/group). Expression was normalized to the 
endogenous controls TATA binding protein (TBP) and ribosomal protein (RP)-L19. Data are expressed as mean 
± SD and asterisks denote a significant temperature effect at α = 0.05 (30 °C vs. 4 °C). 
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Figure 3.4. Cold acclimation of inguinal white adipose tissue (ingWAT) after 3.5 weeks of cold exposure (4 °C 
housing) in male C57BL/6 mice compared to thermoneutral-housed (3 0°C) control mice. Representative bright 
field images (a and b) of Hematoxylin- and Eosin-stained sections of dissected ingWAT taken at 600x 
magnification. Relative mRNA expression (c) of genes related to thermogenesis in ingWAT: uncoupling protein 
1 (UCP1), homeobox protein (HOX)-C9, and hormone-sensitive lipase HSL (n = 8/group). Expression was 
normalized to endogenous controls: ribosomal 18S rRNA, beta-actin, and glyceraldehyde-3 phosphate 
dehydrogenase. All data are expressed as mean ± SD unless not detected (n.d.) and asterisks denote a significant 
temperature effect at α = 0.05 (30 °C vs. 4 °C). 
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Figure 3.5. Cold acclimation of gonadal white adipose tissue (gWAT) after 3.5 weeks of cold acclimation (4 °C 
housing) in male C57BL/6 mice compared to thermoneutral-housed (30 °C) control mice. Representative bright 
field images (a and b) of Hematoxylin- and Eosin-stained sections of dissected gWAT were taken at 600x 
magnification. Relative mRNA expression (c) of genes related to thermogenesis: uncoupling protein 1 (UCP1), 
homeobox protein (HOX)-C9, and hormone-sensitive lipase (HSL) (n = 8/group). For UCP1, n = 6 in the cold 
treatment group as two mice with extremely high relative fold mRNA expression (24 and 1450) were excluded. 
Expression was normalized to the endogenous controls (ribosomal 18S rRNA, beta-actin and glyceraldehyde-3 
phosphate dehydrogenase. All data are expressed as mean ± SD unless not detected (n.d.) and asterisks denote a 
significant temperature effect at α = 0.05 (30 °C vs. 4 °C). 
  
ba
100µm
30ºC 4ºC
UCP1 HOXC9 HSL
0
1
2
3
4
Thermogenic genes
Re
la
tiv
e 
m
RN
A 
ex
pr
es
sio
n 30ºC
4ºC
c
*
 82 
mRNA-Seq and real-time PCR analysis 
 Expression of β3-AR and UCP1 mRNA were significantly higher in iBAT of cold-
acclimated mice compared to iBAT from thermoneutral control mice (Figure 3.3e). VIP, 
PAC1R, VPAC1, and VPAC2 mRNA were detected in iBAT tissue by qPCR (Figure 3.6a). 
Expression of VIP appeared to be higher in the cold-acclimated group, though not significantly 
so. PAC1R mRNA expression was significantly lower in the cold-acclimated group compared 
to the thermoneutral condition. As measured independently with RNA-Seq, the cold-
acclimated group had significantly higher expression of β3-AR, UCP1, and hormone-sensitive 
lipase (HSL) in iBAT than thermoneutral control iBAT samples (Table 3.3). PAC1R mRNA 
expression was detected and confirmed to be lower in the cold-acclimated group. VPAC1, 
VPAC2, VIP, and PACAP mRNA expression was not detected in iBAT of either treatment, 
contrary to real-time qPCR results. 
 Review of qPCR melt curves revealed PAC1R and VPAC1 expression in both the SVF 
and mature adipocyte fractions isolated from iBAT samples from both the thermoneutral and 
col-acclimated mice. Because pooled samples were used for this experiment, standard error 
could not be reported, and consequently, we cannot make conclusions about the relative 
expression of receptor mRNA between the SVF and mature fractions. 
 In primary iBAT-derived adipocytes, PAC1R and VPAC1 were expressed in 
preadipocytes (Figure 3.6b) before differentiation was induced (i.e., with no visible lipid 
droplets), as well as after differentiation (i.e., 70% mature cells with lipid droplets). VPAC1 
expression was significantly increased in mature adipocytes compared preadipocytes. 
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Figure 3.6. Expression of genes related to pituitary adenylate cyclase-activating polypeptide (PACAP) signaling 
in cold-acclimated interscapular brown adipose tissue (iBAT) (a) and cultured primary brown adipocytes (b), 
including vasoactive intestinal peptide (VIP), PACAP receptor 1 (PAC1R), and VIP/PACAP receptor 1 and 2 
(VPAC1/2). iBAT (a) was dissected from male C57BL/6 mice acclimated to cold (4 °C) for 3.5 weeks (n = 
8/group) to mice housed at thermoneutrality (30 °C). Primary brown adipocytes (b) were collected from iBAT of 
non-acclimated (24 °C) mice and adipocytes were pooled from 4 mice for each well (n = 3/group). Expression 
was normalized to the endogenous controls TATA binding protein, and ribosomal protein L-19. All data are 
expressed as mean ± SD unless not detected (n.d.) and asterisks denote a significant temperature effect at α = 0.05 
(30 °C vs. 4 °C) for iBAT (a), and significant differentiation effect for primary cultures (b) 
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Table 3.3. Interscapular brown adipose tissue mRNA sequenced to a 24 million read depth. Log fold change in 
fragments per kilobase million (FKPM) from expression in thermoneutral controls (TN, 30 °C n = 3) compared 
to cold-acclimated animals (C, 4 °C, n = 3). Positive values in green denote higher FKPM in the cold-acclimated 
group, red shows the inverse. Rows 1-7 were chosen as indicators of adaptive thermogenesis and/or lipolysis, 
while expression of experimental genes in rows 8-12 represent PACAP, VIP and the three PACAP receptors. 
 
 
  
Gene Locus q Value Significance Log fold change (C:TN)
β3-AR chr8:27225775-27229588 4.00E-04 *** 0.93
UCP1 chr8:83290347-83298456 4.00E-04 *** 2
HSL chr7:25376818-25566417 2.26E-02 * 0.57
DIO2 chr12:90724551-90738438 4.00E-04 *** 1.49
PGC-1α chr5:51454248-51553921 7.40E-04 *** 0.66
PGC-1β chr18:61298135-61400431 6.82E-01 n.s. 0.11
COX chr11:90638183-90687601 4.00E-04 *** 1.02
PAC1R chr6:55451977-55501455 4.00E-04 *** -1.78
PACAP chr17:93199017-93206537 n.d. n/a n/a
VPAC1 chr9:121642716-121672954 n.d. n/a n/a
VPAC2 chr12:116077726-116159604 n.d. n/a n/a
VIP chr10:5639139-5647617 n.d. n/a n/a
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 ingWAT from the cold-acclimated group had significantly higher mRNA expression 
of UCP1 and hormone-sensitive lipase (gene name LIPE) compared to the thermoneutral 
ingWAT (Figure 3.5). Two PACAP receptors, PAC1R and VPAC1, were expressed in this 
depot, with PAC1R expression significantly increased in response to cold exposure (Figure 
3.7a). In contrast, VPAC2 and PACAP mRNA were detected in only a few ingWAT samples 
and in all samples exceeded or approached the limit of detection (≥35 CT). Therefore, it was 
not possible to assess the expression levels between groups with any degree of confidence and 
these genes were considered to be undetectable (n.d.) with our reaction conditions. PAC1R and 
VPAC1 were expressed in preadipocytes isolated from ingWAT and in differentiated cultures 
(Figure 3.7b), but the expression level did not differ pre- and post-differentiation. 
 UCP1 mRNA was not induced in gWAT isolated from cold-acclimated mice (Figure 
3.5c) and was the only adipose tissue with a significant decrease in the expression of HSL in 
the cold-acclimated group. In gWAT from the cold-acclimated group compared to 
thermoneutral gWAT, PAC1R, VIP, and VPAC1 mRNA were expressed and PAC1R mRNA 
expression was significantly decreased (Figure 3.8a). Similar to ingWAT, VPAC2 and PACAP 
mRNA were not detected in all samples and when detected, were approaching the limit of 
detection (≥35 CT). PAC1R and VPAC1 were expressed in primary preadipocytes and 
differentiated adipocytes (Figure 3.8b) and PAC1R expression was significantly higher in 
differentiated cultures (≥70% cells containing large lipid droplets). 
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Figure 3.7. Expression of genes related to pituitary adenylate cyclase-activating polypeptide (PACAP) signaling 
in cold-acclimated inguinal white adipose tissue (ingWAT) (a) and cultured primary white adipocytes (b) from 
ingWAT, including vasoactive intestinal peptide (VIP), PACAP receptor 1 (PAC1R), and VIP/PACAP receptor 
1 and 2 (VPAC1/2). ingWAT (a) was dissected from male C57BL/6 mice acclimated to cold (4 °C) for 3.5 weeks 
(n = 8/group) to mice housed at thermoneutrality (30 °C). VPAC2 was detected (at levels nearing the limit of 
detection (Ct > 35)) only in some ingWAT samples from both treatment groups and was therefore considered to 
be not detected. Primary white adipocytes (b) were collected from ingWAT of non-acclimated (24 °C) mice and 
adipocytes were pooled from 4 mice for each well (n = 3/group). Expression was normalized to endogenous 
controls: ribosomal 18S rRNA, beta-actin, and glyceraldehyde-3 phosphate dehydrogenase. All data are expressed 
as mean ± SD unless not detected (n.d.) and asterisks denote a significant temperature effect at α = 0.05 (30 °C 
vs. 4 °C) for acclimated ingWAT (a), and significant differentiation effect for primary cultures (b). 
 
  
VIP PAC1R VPAC1 VPAC2 PACAP
0
1
2
3
ingWAT
R
el
at
iv
e 
m
R
N
A
 e
xp
re
ss
io
n
30ºC
4ºC
n.d. n.d.
*
a
PAC1R VPAC1
0
1
2
3
ingWAT
R
el
at
iv
e 
m
R
N
A
 e
xp
re
ss
io
n
Preadipocytes
Differentiated
b
 87 
 
 
Figure 3.8. Expression of genes related to pituitary adenylate cyclase-activating polypeptide (PACAP) signaling 
in cold-acclimated gonadal white adipose tissue (gWAT) (a) and cultured primary white adipocytes (b) from 
ingWAT, including vasoactive intestinal peptide (VIP), PACAP receptor 1 (PAC1R), and VIP/PACAP receptor 
1 and 2 (VPAC1/2). gWAT (a) was dissected from male C57BL/6 mice acclimated to cold (4 °C) for 3.5 weeks 
(n = 8/group) to mice housed at thermoneutrality (30 °C). VPAC2 was detected (at levels nearing the limit of 
detection (Ct > 35)) only in some ingWAT samples from both treatment groups and was therefore considered to 
be not detected. Primary white adipocytes (b) were collected from gWAT of non-acclimated (24 °C) mice and 
adipocytes were pooled from 4 mice for each well (n = 3/group). Expression was normalized to endogenous 
controls: ribosomal 18S rRNA, beta-actin, and glyceraldehyde-3 phosphate dehydrogenase. All data are 
expressed as mean ± SD unless not detected (n.d.) and asterisks denote a significant temperature effect at α = 
0.05 (30 °C vs. 4 °C) for acclimated gWAT (a), and significant differentiation effect for primary cultures (b). 
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Lipolysis 
 Acute treatment of differentiated brown adipocytes with Maxadilan, a PAC1R-specific 
agonist or with PACAP, which stimulates all three PACAP receptors, did not alter FFA or 
glycerol release compared to saline treated control adipocytes (Figure 3.9). 
 Selective stimulation of the VPAC1 and VPAC2 receptors with PACAP while blocking 
stimulation of PAC1R with M65 did not increase either measure of lipolysis but did increase 
the variance of measurements of glycerol and free fatty acid in the media of brown primary 
adipocyte cultures (Figure 3.9). In differentiated preadipocytes of either iBAT or ingWAT, 
FFA release and glycerol release were significantly increased in the presence of the β3-AR 
specific agonist, CL316,243 (Figure 3.10), but addition of PACAP receptor agonists with 
CL316,243 did not enhance the levels of lipolysis seen in response to CL316,243 alone. 
 Acute treatment of white adipocytes with Maxadilan did not alter FFA or glycerol 
release compared to controls (Figure 3.11). FFA release and glycerol release were significantly 
increased in the presence of the β3-AR specific agonist, CL316,243, but this effect was not 
enhanced by PACAP receptor agonism in differentiated preadipocytes of ingWAT (Figure 
3.12). 
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Figure 3.9. Lipolysis in primary brown adipocyte cultures following 2-hour stimulation of pituitary adenylate 
cyclase-activating polypeptide (PACAP) receptors. Free fatty acid (a) and glycerol (b) release were measured in 
media of differentiated primary cultures from interscapular brown adipose tissue of male C57BL/6 mice (n = 2 
wells/treatment). Patterns of receptor agonism (+) were achieved using CL316,243 to stimulate b3 adrenergic 
receptor (b3-AR) as a positive control, pituitary adenylate cyclase-activating polypeptide (PACAP) for non-
specific simultaneous stimulation of VPAC1, VPAC2, and PAC1R, Maxadilan for PAC1R-specific activation, 
and M65 (PAC1R-specific antagonist) plus PACAP to stimulate only VPAC1 and 2 but not PAC1R. Data are 
expressed as mean ± SD and asterisks denote a significant effect of treatment at α = 0.05 (stimulated vs. saline 
vehicle control). 
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Figure 3.10. Lipolysis in primary brown adipocyte cultures following 2-hour stimulation of pituitary adenylate 
cyclase-activating polypeptide (PACAP) receptors in combination with b3 adrenergic receptor (b3-AR). Free fatty 
acid (a) and glycerol (b) release were measured in media of differentiated primary cultures from interscapular 
brown adipose tissue of male C57BL/6 mice (n = 2 wells/treatment). Patterns of receptor agonism (+) were 
achieved using CL316,243 to stimulate b3 adrenergic receptor (b3-AR), pituitary adenylate cyclase-activating 
polypeptide (PACAP) for non-specific simultaneous stimulation of VPAC1, VPAC2, and PAC1R, Maxadilan for 
PAC1R-specific activation, and M65 (PAC1R-specific antagonist) plus PACAP to stimulate VPAC1 and 2 but 
not PAC1R. Data are expressed as mean ± SD and asterisks denote a significant effect of treatment at α = 0.05 
(stimulated vs. saline vehicle control). 
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Figure 3.11. Lipolysis in primary white adipocyte cultures following 2-hour stimulation of pituitary adenylate 
cyclase-activating polypeptide (PACAP) receptors. Free fatty acid (a) and glycerol (b) release were measured in 
media of differentiated primary cultures from inguinal white adipose tissue of male C57BL/6 mice (n = 2 
wells/treatment). Patterns of receptor agonism (+) were achieved using CL316,243 to stimulate b3 adrenergic 
receptor (b3-AR) as a positive control, pituitary adenylate cyclase-activating polypeptide (PACAP) for non-
specific simultaneous stimulation of VPAC1, VPAC2, and PAC1R, Maxadilan for PAC1R-specific activation, 
and M65 (PAC1R-specific antagonist) plus PACAP to stimulate only VPAC1 and 2 but not PAC1R. Data are 
expressed as mean ± SD and asterisks denote a significant effect of treatment at α = 0.05 (stimulated vs. saline 
vehicle control). 
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Figure 3.12. Lipolysis in white adipocyte cultures following 2-hour stimulation of pituitary adenylate cyclase-
activating polypeptide (PACAP) receptors in combination with b3 adrenergic receptors (b3-ARs). Free fatty acid 
(a) and glycerol (b) release were measured in media of differentiated primary cultures from inguinal white adipose 
tissue of male C57BL/6 mice (n = 2 wells/treatment). Patterns of receptor agonism (+) were achieved using 
CL316,243 to stimulate b3 adrenergic receptor (b3-AR), pituitary adenylate cyclase-activating polypeptide 
(PACAP) for non-specific simultaneous stimulation of VPAC1, VPAC2, and PAC1R, Maxadilan for PAC1R-
specific activation, and M65 (PAC1R-specific antagonist) plus PACAP to stimulate VPAC1 and 2 but not 
PAC1R. Data are expressed as mean ± SD. and asterisks denote a significant effect of treatment at α = 0.05 
(stimulated vs. saline vehicle control). 
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Oxygen consumption measurements 
 Acute treatment of differentiated brown adipocytes with PACAP receptor agonists  in 
vitro did not alter the rate of oxygen consumption compared to saline controls (Figure 3.13). 
Oxygen consumption rate was significantly increased by CL316,243. Addition of PACAP 
receptor agonists along with CL316,243 did not enhance the rate of oxygen consumption 
compared to the response to CL316,243 alone in differentiated primary adipocytes of iBAT. 
In our modified version of the Mito Stress Kit assay, 10 mM CL316,243 stimulated brown 
adipocyte oxygen consumption as significantly as 3 µM FCCP (Figure 3.14).  
 Acute treatment of differentiated white adipocytes with PACAP receptor agonists in 
vitro also did not alter oxygen consumption compared to controls (Figure 3.15). Oxygen 
consumption rate was significantly increased by CL316,243, but not enhanced in combination  
with PACAP receptor agonists compared to CL316,243 alone. In our modified version of the 
Mito Stress Kit assay, 10 mM CL316,243 significantly increased oxygen consumption in 
differentiated primary white adipocytes, and subsequent addition of FCCP increased oxygen 
consumption significantly further (Figure 3.16). 
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Figure 3.13. Activation of thermogenesis in primary brown adipocyte cultures following acute stimulation of 
pituitary adenylate cyclase-activating polypeptide (PACAP) receptors alone or in combination with b3 adrenergic 
receptor (b3-AR). Oxygen consumption rate was measured in media of primary cultures of adipocytes from 
interscapular brown adipose tissue from male C57BL/6 mice (n = 7 wells per treatment). Mitochondrial 
respiration was brought to a minimum using Oligomycin, receptors were selectively stimulated, and then the 
difference (D) in oxygen consumption calculated. Patterns receptor agonism (+) were achieved using CL316,243 
to stimulate b3 adrenergic receptor (b3-AR), pituitary adenylate cyclase-activating polypeptide (PACAP) for non-
specific simultaneous stimulation of VPAC1, VPAC2, and PAC1R, and Maxadilan for PAC1R-specific 
activation. Data are expressed as mean ± SD and asterisks (*) denote a significant effect (α = 0.05) of treatment 
compared to vehicle (-) control, while daggers (†) denote a significant effect of treatment compared to b3-AR 
stimulated (+) control. 
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Figure 3.14. Oxygen consumption profile of differentiated primary brown adipocytes of interscapular origin (a) 
and differentiated primary white adipocytes of inguinal origin (b) from C57BL/6 mice (n = 7/treatment) during 
the Mitochondrial Stress Test Kit assay (Agilent, Santa Clara, CA, USA). During the Agonist stage, either saline 
vehicle (black dots) or CL316,243, a specific β3-AR agonist (gray boxes) was added. Data are expressed as mean 
± SD and asterisks denote a significant effect of treatment at α = 0.05 (stimulated vs. PBS vehicle control). 
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Figure 3.15. Activation of thermogenesis in primary white adipocyte cultures following acute stimulation of 
pituitary adenylate cyclase-activating polypeptide (PACAP) receptors alone or in combination with b3 adrenergic 
receptor (b3-AR). Oxygen consumption rate was measured in media of primary cultures of adipocytes from 
inguinal white adipose tissue from male C57BL/6 mice (n = 7 wells per treatment). Mitochondrial respiration was 
brought to a minimum using Oligomycin, receptors were selectively stimulated, and then the difference (D) in 
oxygen consumption calculated. Patterns receptor agonism (+) were achieved using CL316,243 to stimulate b3 
adrenergic receptor (b3-AR), pituitary adenylate cyclase-activating polypeptide (PACAP) for non-specific 
simultaneous stimulation of VPAC1, VPAC2, and PAC1R, and Maxadilan for PAC1R-specific activation. Data 
are expressed as mean ± SD and asterisks (*) denote a significant effect (α = 0.05) of treatment compared to 
vehicle (-) control, while daggers (†) denote a significant effect of treatment compared to b3-AR stimulated (+) 
control. 
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Figure 3.16. Oxygen consumption profile of differentiated primary brown adipocytes of interscapular origin (a) 
and differentiated primary white adipocytes of inguinal origin (b) from C57BL/6 mice (n = 7/treatment) during 
the Mitochondrial Stress Test Kit assay (Agilent, Santa Clara, CA, USA). During the Agonist stage, either 
saline vehicle (black dots) or CL316,243, a specific β3-AR agonist (gray boxes) was added. Data are expressed 
as mean ± SD and asterisks denote a significant effect of treatment at α = 0.05 (stimulated vs. PBS vehicle 
control). 
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3.4 DISCUSSION 
Whole-animal and organ-level acclimation 
 As expected, mice in the cold-acclimated group had significantly lower body mass 
compared to the thermoneutral group due to the greater energetic requirements required to 
maintain an internal body temperature of 37 °C in the face of an external temperature of 4 °C 
(Figure 3.2a). The fat mass of cold-acclimated mice was significantly lower than the fat mass 
of mice housed at thermoneutrality by 2 weeks of acclimation (Figure 3.2c), as mice depleted 
lipid stores within adipose tissue to fuel shivering in muscle and adaptive thermogenesis in the 
BAT. Lean mass was not significantly different between the groups after 3.5 weeks, which 
shows that the differences in body mass and fat composition were not due to reduced growth 
or malaise (Figure 3.2b). Adipose tissues examined-post dissection revealed that gWAT and 
ingWAT depots from cold-acclimated mice weighed significantly less than the same adipose 
tissue depots from mice housed at thermoneutrality, while BAT mass did not differ between 
groups (Figure 3.2d). The loss of white adipose tissue mass results from mobilization of lipid 
stores to fuel thermogenesis and is a well-documented outcome of cold acclimation182. While 
some groups report increased BAT mass following cold exposure as brown adipocytes undergo 
hyperplasia during cold exposure177, the increase in adaptive thermogenesis requires utilization 
of intracellular lipid stores and thus these two processes compete such that overall iBAT mass  
is increased, decreased, or unchanged after cold exposure depending on the strain of mouse 
and species examined 64,182,211. 
 As expected, iBAT from cold acclimated mice showed morphological and molecular 
characteristics of increased thermogenic activity, including increased mitochondria as 
determined from the darker pink eosin staining (a non-specific protein stain) (Figure 3.3a,b) 
and a darker brown colour upon dissection indicative of increased mitochondrial content190. 
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Histological analysis of sections revealed smaller cells with lower lipid content (Figure 3.3c,d) 
and gene expression analysis reveal increased thermogenic gene expression (UCP1) and 
sympathetic sensitivity (β3-AR) in iBAT from cold acclimated mice (Figures 3.3e). These data 
outline a complete morphological, histological, and genetic acclimation to cold. 
 In this robust model of thermogenic activation, PAC1R was significantly down-
regulated in cold-acclimated iBAT, suggesting that contrary to our hypothesis, PACAP action 
directly at the adipocyte is not an important activator of the thermogenic response in this tissue 
(Figure 3.6a). Since PACAP mRNA could not be detected in this tissue in either group, PACAP 
is not an adipokine involved in thermogenesis. The discovery of PAC1R in this tissue and its 
downregulation after cold-acclimation were nonetheless interesting and we therefore set out 
identify the cell types within adipose tissue that were expressing PAC1R. PACAP receptors 
are known to be expressed in immune cells, such as macrophages212, that have been isolated 
from adipose tissues. Therefore, we measured the expression of these receptors in cultures of 
adipocytes that are free from contaminating tissues. Interestingly, adipocytes isolated from 
iBAT express the PAC1R, with a trend of increased expression in differentiated adipocytes 
compared to preadipocytes (Figure 3.6b), although this result was not statistically significant. 
This shows, for the first time, that adipocytes themselves express PAC1R and that the detection 
of its mRNA in whole adipose tissue was not solely derived from macrophage, endothelial, 
and/or nerve cell expression. 
 Sequencing of mRNA from iBAT samples supported the real-time data for PAC1R but, 
interestingly, sequence reads encoding VIP and the VPAC receptors were not detected despite 
the mRNA having been sequenced to a depth of 24 million reads or more (Table 3.3). It is 
generally accepted that mRNA-Seq is a more sensitive method than real-time qPCR. The 
discrepancy between the qPCR results and the sequencing results is unusual, but both datasets 
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agree that PAC1R is expressed in iBAT of both cold-acclimated as well as thermoneutral mice, 
and that PAC1R expression is significantly lower in the cold-acclimated samples. Of note, 
UCP1 was the only other gene from this study with a higher degree of change than PAC1R. 
This suggests that a large reduction of PAC1R mRNA may be important in iBAT’s response 
to cold acclimation, although the functional significance of this is not yet known. 
 As expected, ingWAT showed signs of browning with cold acclimation confirming that 
sufficient cold exposure had occurred to initiate patchwork thermogenic programing in this 
adaptable tissue. Brite adipocytes are quite unlike neighbouring white adipocytes as can be 
seen in the ingWAT of cold-acclimated mice (Figure 3.4a) but not their thermoneutral 
counterparts (b). 
 The thermogenically competent adipose depots of ingWAT also experienced an 
expected and significant upregulation of UCP1 mRNA in the cold-acclimated  group (Figure 
3.4c), which is known to correlate with greater thermogenic capacity of the adipocytes 
(reviewed in Nedergaard, et al. 179). While the cold-induced upregulation of UCP1 mRNA in 
ingWAT was higher than that seen in iBAT, previous studies show that the thermogenic 
capacity of iBAT is still higher73,178. This paradox is due to the very low basal UCP1 mRNA 
expression in thermoneutral ingWAT, which mathematically inflates the calculated fold 
induction in cold-acclimated ingWAT since the expression is calculated as a relative induction. 
 Studies have shown that HOXC9 is a WAT-specific marker whose expression is 
retained through the browning process213. As expected, we found no significant upregulation 
of HOXC9 mRNA in ingWAT in response to cold acclimation (Figure 3.4c). These findings 
show that the ingWAT underwent normal physiological browning with an increase in UCP1 
mRNA and retention of genetic markers of WAT despite the activation of the thermogenic 
program. 
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 As we had hypothesized, PACAP receptors were significantly increased in cold-
acclimated ingWAT (Figure 3.7a), but without a corresponding cold-induced increase in iBAT, 
lack of PACAP mRNA expression in adipocytes, and lack of PAC1R mRNA upregulation in 
differentiated primary adipocytes compared to preadipocytes from ingWAT (Figure 3.7b), it is 
unlikely that this is indicative of a direct effect on the regulation of thermogenic genes. 
Therefore, these results initially suggest a role for PACAP in thermogenic activation of 
ingWAT, but not all lines of evidence corroborate this finding. Further study will be required 
to define the role of PACAP in ingWAT acclimation to cold. 
 Adipose tissue from the gWAT depot showed an expected lack of thermogenic 
enhancement with cold acclimation, including the absence of brite cells and retention of cells 
dominated by a single, unilocular lipid droplet (Figure 3.5a,b). UCP1 expression did not differ 
between gWAT samples from thermoneutral and cold-acclimated mice (Figure 3.5c). Similar 
to ingWAT results, gWAT retained expression of HOXC9, showing normal levels of WAT-
specific genetic markers throughout the process of acclimation to cold. 
 PAC1R was shown for the first time to be expressed in gWAT and was significantly 
down-regulated in cold-acclimated gWAT tissue compared to gWAT isolated from mice 
housed at thermoneutrality (Figure 3.8a). Furthermore, PAC1R expression was significantly 
higher in differentiated gWAT adipocytes than gWAT preadipocytes (Figure 3.8b). Taken 
together these results show that PAC1R expression is regulated in gWAT, and future studies 
including cultures of adipocytes from gWAT with genetic deletion of PAC1R could be utilized 
to interrogate PACAP’s role in metabolic pathways of gWAT adipocytes. 
 PACAP itself was not detected using qPCR in any of the adipose tissues tested (Figures 
3.6-3.8). This was somewhat surprising given previous reports of PACAP mRNA expression 
in human visceral adipose tissue214. Thus, our results suggest that mouse adipose tissues do not 
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express PACAP and that is not an important murine adipokine regulating adipose tissue 
function during cold acclimation. Additionally, the pattern of PAC1R gene expression in cold-
acclimated BAT and WAT does not clearly suggest PACAP signalling to be a key regulator of 
adaptive thermogenesis in cold-acclimated adipocytes. 
 
PACAP does not participate in β3-AR-stimulated lipolysis or thermogenesis 
 The expression and genetic control of PAC1R mRNA in response to cold stress across 
all three adipose tissues calls to question its functional significance in adipocyte biology. 
PACAP acting centrally109,110, and norepinephrine acting peripherally215, are both important 
modulators of the thermogenic response of BAT107. There is currently no evidence in the 
literature indicating PACAP can bind PACAP receptors expressed on adipocytes to 
peripherally affect energy expenditure. In fact, the first evidence of PAC1R expression in 
brown adipocytes was published by the Gray lab last year168. To assess a functional role for 
PACAP in adipocytes, we measured the effect of PACAP agonism on lipolysis and oxygen 
consumption. These were selected because the liberation of free fatty acids and increased 
oxygen consumption at the inner mitochondrial membrane are hallmarks of increased 
thermogenic activation by beige and brown adipocytes64,177. Stimulation of the β3-AR in 
adipocytes results in the well-characterized activation of heterotrimeric G proteins, 
downstream adenylyl cyclase activation, adipocyte lipolysis and, finally, oxygen consumption 
in thermogenic adipocytes. Free fatty acids provide fuel for thermogenesis and acutely activate 
UCP1, thereby uncoupling ATP production and dissipating stored energy in lipids as heat. 
Increased oxygen consumption results in part from utilization in the β-oxidation process but 
mainly from O2 utilization by Complex IV of the mitochondrial electron transport chain where 
oxygen acts as the final electron acceptor during cellular aerobic respiration. PACAP receptors 
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are known to modulate energy balance in the hypothalamus216 and to activate adenylate 
cyclase82 and so we were interested in the idea that PACAP could independently activate 
lipolysis and thermogenesis peripherally in adipocytes or act to modulate the effect of 
adipocyte β3-AR stimulation by the β3-specific agonist CL316,243, through the interaction of 
signalling pathways. 
 Previous work measuring lipolytic rates following β3-AR agonism in vivo suggests that 
white adipocytes excrete free fatty acids at greater rates than brown adipocytes217. This may 
result from the primary role of white adipose tissue in the storage and release of lipids in times 
of energetic need. Higher lipolytic rates were therefore expected for ingWAT cultures 
compared to iBAT. Contrary to those expectations, release of FFA to the media was similar 
between brown and white adipocytes cultures (Figures 3.9a and 3.11a) and ingWAT cultures 
had roughly 2 times higher glycerol release than iBAT (Figure 3.9b and 3.11b). Previous 
reports have shown increases in oxygen consumption by stimulating intact culture brown 
adipocytes218 as well as isolated mitochondria178 with CL316,243. Our methods provided 
similar results, with oxygen consumption rate increasing significantly in differentiated brown 
preadipocytes upon CL316,243 treatment (Figure 3.13). Adipocytes isolated from iBAT have 
higher mitochondrial content than white adipose tissues, and a greater relative concentration 
of carrier proteins in the mitochondria178. Therefore, we were not surprised to see that cultures 
of ingWAT adipocytes provided a lower induction of oxygen consumption upon CL316,243 
stimulation (Figure 3.15). In summary, these data suggest successful differentiation of 
preadipocyte cultures to give mature adipocytes that respond appropriately to adrenergic 
stimuli. 
 We hypothesized that PAC1R stimulation is capable of initiating lipolysis and acute 
thermogenic activity in cultured brown adipocytes. Thus, we expected the addition of the 
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synthetic agonist Maxadilan (PAC1R) or the natural ligand PACAP (stimulates PAC1R, 
VPAC1 and VPAC2) would increase the release of glycerol, release of free fatty acids, and 
consumption of oxygen in the media. Alternatively, we hypothesized that simultaneously 
stimulating β3-ARs and PACAP receptors would increase lipolysis and oxygen consumption 
above the level of β3-AR stimulation alone. This latter hypothesis would indicate that PACAP 
was capable of potentiating the stimulatory effects of β3-AR. Contrary to our expectations, 
stimulating PACAP receptors alone in the adipocyte cultures did not elicit any change in FFA, 
glycerol, or oxygen measurements for brown (Figures 3.9 and 3.13) or white (Figures 3.11 and 
3.15) cultures. Furthermore, addition of PACAP with CL316,243 did not potentiate stimulation 
of iBAT (Figure 3.10) or ingWAT (Figure 3.12) above the level of CL316,243 stimulation 
alone . Collectively, these data suggest that PACAP does not independently activate lipolysis 
or thermogenesis or potentiate the adrenergic response at the level of the adipocyte in ingWAT 
or iBAT. This was surprising considering unpublished results from single-cell sequencing data 
from human adipocytes, which show a strong correlation between the expression level of 
PAC1R and lipolysis-related genes (personal communication with Arthe Raajendiran219). 
 It is possible that the ability of PACAP to augment adrenergic-stimulated lipolysis and 
oxygen consumption may have been masked by the high levels of CL316,243 used. If β3-AR 
stimulation was intense enough that mitochondrial respiration was maximally activated, this 
could have saturated pathways responsible for the physiological measurements that we used in 
this study. Figure 3.14 shows that CL316,243-stimulated brown adipocyte cultures displayed 
oxygen consumption levels similar to FCCP, which is the theoretical maximum. This indicates 
that even if a higher concentration of CL316,243 had been added, there would not have been 
an increase in oxygen consumption above that level. To the best of our knowledge, there are 
no pharmacological stimuli capable of enhancing adipocyte oxygen consumption higher than 
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FCCP. To better characterize the response to CL316,243, a titration curve should be run to 
determine a half-maximal stimulation. In this half-maximally stimulated state, addition of 
Maxadilan may reveal a modulatory effect. 
 
Future prospects 
 Since these findings show that PAC1R mRNA expression is significantly regulated in 
adipose tissues in vivo in response to cold stress, but is not associated with any acute effect on 
lipolysis or thermogenesis in the main thermogenic adipose tissue iBAT, or the 
thermogenically inducible adipose tissue ingWAT, future work in this field should interrogate 
the alternative hypothesis that PACAP is important in stimulating adaptive processes for long-
term acclimation to cold. To test this hypothesis, I would perform two experiments. First, I 
would assess the effect of PACAP on the differentiation of primary brown adipocytes in culture 
to determine whether PACAP enhances differentiation of thermogenic adipocytes thus 
increasing the functional capacity of BAT to perform thermogenesis. Secondly, I would assess 
genetic markers of thermogenesis in cultured adipocytes differentiated in the presence or 
absence of PACAP and/or isoproterenol to determine if PACAP can augment adrenergic-
induced differentiation. Lastly, it is also possible that PAC1R mRNA expression are only 
transiently expressed in the acclimation to cold or differentiation, as many other factors are72,220 
and thus we missed a short period of PAC1R mRNA induction in iBAT. To test this, adipose 
tissues should be collected from mice at different time points in the acclimation process and 
qPCR used to test for PAC1R expression. 
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3.5 CONCLUSION 
 Current evidence in the literature suggests that PACAP is an important central regulator 
of the thermogenic response to cold stress in mice, but little is known about the effect of 
PACAP directly at the adipocyte. Here we have shown that PAC1R mRNA expression may be 
important in the adipose acclimation to long-term cold exposure. PAC1R and VPAC1 mRNA 
were expressed in the three physiologically distinct adipose tissue depots investigated, and the 
pattern of expression differs depending on depot type and housing temperature. These 
receptors were also expressed in preadipocytes and differentiated adipocytes in cultures of all 
three depots, demonstrating for the first time PACAP receptor expression in adipocytes 
themselves. The lack of observed effect on the rates of lipolysis or oxygen consumption with 
acute pharmacological stimulation of PAC1R suggests that this receptor does not activate 
thermogenesis in mature adipocytes, but we have not tested the effects of chronic stimulation 
of the PAC1R on adipocyte differentiation and function. The work presented here has added 
to the growing body of literature that supports a role for PACAP in energy regulation including 
in the context of adaptive thermogenesis and will inform future work attempting to re-balance 
the energy equation for the treatment of obesity and diabetes. 
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Chapter Four: Concluding Remarks on AAV Development and 
the Expression of PACAP Receptors in Adipocytes  
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4.1 SUMMARY 
 This thesis was completed to (A) develop a viral gene therapy tool to study the effects 
of pituitary adenylate cyclase-activating polypeptide (PACAP) expression specifically in the 
ventromedial nucleus (VMH) of the hypothalamus and (B) address the hypothesis that PACAP 
may enhance adaptive thermogenesis by acting peripherally at the adipocyte. 
The objectives of this research were the following: 
1. Develop a stereotaxic injection protocol and perform intracerebral injections of adeno-
associated virus (AAV). 
2. Assess the performance of the AAV vector and accompanying plasmid pscAAV9-SF1-
GFP for inducing enhanced green fluorescent protein (EGFP) gene expression in the 
VMH in vivo.  
3. Produce a mouse model of maximal thermogenic activation and assess the genetic 
regulation of PACAP and PACAP receptor expression in adipose tissues.  
4. Determine whether PACAP or its receptors are expressed specifically on mouse 
adipocytes.  
5. Assess the lipolytic and thermogenic consequences of acute PACAP receptor activation 
on mouse adipocytes in vitro.  
 Chapter Two addressed objectives 1 and 2 above with the future aim of developing a 
tool (Figure 2.2) that could be used to restore PACAP expression specifically in the VMH of 
PACAP-null mice, thus providing a genetic model to assess the contribution of the VMH to 
energy balance including thermogenesis. The efficacy of the plasmid and its vector were 
assessed by detection and localization of EGFP expression using fluorescent microscopy. 
Results showed successful induction of EGFP expression in the VMH-targeted, but not 
intracerebroventricular-targeted strategy (Figure 2.4). Due to the high viral concentration used, 
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some off-target expression was detected (Figures 2.4 and 2.5) and thus I have recommended 
lower viral dosage to prevent steroidogenic factor 1 (SF1) promoter leakiness. EGFP was 
detected superior to the VMH, and thus I also recommend modification of the injection 
coordinates for future studies. The successful induction of EGFP expression in the 
hypothalamus was an important and positive step towards the larger goal of VMN-specific 
PACAP rescue in PACAP-null mice.  
 Chapter Three addressed objectives 3-5 above, which were designed to evaluate the 
potential for peripheral activation of thermogenesis by PACAP at the level of the adipose 
tissue. The mouse model of maximal thermogenic acclimation developed here was confirmed 
to meet the genetic, histological, and morphological changes expected based on previous 
work64,72,177,179 (Figures 3.2-3.5). We then measured PACAP receptor expression in adipose 
tissues of this model and found that the results did not support our hypothesis that PAC1R 
mRNA expression would be significantly increased in cold-acclimated brown adipose tissue 
(BAT). However, these data show the first documented evidence of PAC1R expression in BAT 
and provide the first robust analysis of PACAP receptor expression in white adipose tissue and 
BAT under cold exposure (Figures 3.6-3.8). Interestingly, PACAP receptor expression was 
increased in inguinal and decreased in gonadal white adipose tissue, showing depot-specific 
patterning of the PAC1 receptor. Isolated mature adipocytes and preadipocytes of BAT showed 
expression of the PACAP-specific receptor, confirming adipocyte  PAC1R expression. In vitro 
functional data did not support the hypothesis that PACAP could acutely induce lipolysis or 
thermogenesis via PAC1R alone, or in combination with adrenergic receptor agonism (Figures 
3.9-3.16). Future work should address the possibility that long-term PACAP treatment could 
enhance the thermogenic capacity of adipocytes. 
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4.2 SIGNIFICANCE 
 Obesity and its comorbidities account for a significant portion of the health care burden, 
decrease quality of life for patients, and increase the risk of death. Current strategies of 
increasing exercise and decreasing food intake have not been successful in curbing the 
increasing prevalence of this disease. Environmental factors such as poor urban planning that 
prohibit active lifestyle choices have contributed to the obesity epidemic, but dysregulated 
energy metabolism is the driver of the disease and must be better understood in order to provide 
comprehensive treatment strategies. Energy metabolism is controlled by nutritional, hormonal, 
and neuronal signals working in concert. Hormonal regulation of energy balance has gained 
interest as a therapeutic target and this substantial field continues to expand with the 
identification of a number of extremely promising molecular targets to better understand and 
treat obesity and T2D.  
 Here we investigated two approaches to understanding energy balance under the 
influence of the therapeutically intriguing neuropeptide PACAP, which is involved in the 
regulation of sympathetic output to peripheral effector organs, including BAT, to alter energy 
expenditure. The first approach we used targeted the hypothalamic VMH, which is an essential 
energy regulating brain centre that is known to regulate food intake and energy expenditure to 
alter body mass. In the VMH, PACAP is localized to the same neurons as orexigenic and 
anorexigenic hormones such as proopiomelanocortin, neuropeptide Y, Agouti-related peptide, 
and brain-derived neurotrophic factor, suggesting that it may play an important role in the 
regulation or integration of energy-modulating pathways within this nucleus. Neuroanatomical 
and pharmacological evidence also implicate PACAP as an important neuropeptide in other 
hypothalamic nuclei, but it is difficult to discern the relative contribution and hierarchy of 
hypothalamic nuclei in thermogenic activation. Thus, we have proposed an AAV-mediated 
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genetic strategy to restore PACAP specifically in the VMH to assess its effectiveness in 
rescuing the thermogenically-impaired phenotype of PACAP-null mice. AAV-mediated gene 
therapy techniques are becoming more common in the clinical setting. While some technical 
difficulties remain, the work presented here has provided preliminary evidence that the virus 
and accompanying plasmid developed by the Gray lab are effective in inducing gene 
expression using the SF1 promoter. Future completion of VMH-specific genetic rescue of 
PACAP will be a powerful tool to understand the hypothalamic regulation of energy balance, 
including thermogenesis, and will help in understanding the mechanisms that can lead to 
negative energy balance and ameliorate obesity and its metabolic complications. 
 The second approach targets the adipose tissue directly to better elucidate PACAP’s 
role in energy metabolism. Sympathetic outputs controlled by the hypothalamus have long 
been known to initiate thermogenesis in BAT, and central administration of PACAP has proven 
effective in activating adaptive thermogenesis, but the current literature does not address the 
possibility that PACAP may act as a peripheral activator of thermogenesis by binding directly 
to adipocytes. The data presented here are, to the best of our knowledge, the first documented 
evidence of PAC1R mRNA expression in BAT and provide the first robust analysis of PACAP 
receptor expression in adipose tissues of a model of thermogenic activation. The discovery of 
PAC1R mRNA in BAT provides an exciting opportunity to expand the understanding of 
hormonal regulation within this tissue and in the larger context of energy balance. Further, the 
significant regulation of a number of PACAP receptors across three functionally distinct 
adipose tissue in this model adds to the growing evidence that PACAP and its receptors are 
essential components at various levels of stress axes. The preliminary assessment of PAC1R 
function in adipose tissue did not provide evidence for acute lipolytic or thermogenic activation 
in vitro, but further work is required to fully understand the role of this receptor in adipose 
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function. The ability to target energy expenditure directly at the adipocyte may provide a 
promising therapeutic strategy due to the specificity of PAC1R splice variant expression across 
tissues.  
 In summary, this thesis has contributed to a more comprehensive understanding of the 
energy-regulating peptide PACAP and has aided the development of tools available to 
elucidate the roles of PACAP in hypothalamic nuclei, which will inform efforts to develop 
better anti-obesity strategies oriented towards novel molecular targets. Specificity is an 
essential component in the development of therapeutics and in understanding the complicated 
regulatory networks in the central nervous system. The viral reintroduction of PACAP 
specifically to the VMH and discovery of its highly spliced receptor PAC1R in BAT both 
provide opportunities to enhance the targeting of research and therapeutics that aim to utilize 
adaptive thermogenesis as an energy expenditure mechanism in the prevention and treatment 
of obesity and type 2 diabetes. 
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List of Abbreviations  
AAV9 adeno-associated virus, serotype 9 
Acetyl-CoA acetyl-coenzyme A 
ACTH adrenocorticotropin-releasing hormone 
ACUC animal care and use committee 
AgRP Agouti-related peptide 
ANS autonomic nervous system 
ARH arcuate nucleus (of the hypothalamus) 
ATP adenosine triphosphate 
BAT  brown adipose tissue 
BDNF  brain-derived neurotropic factor 
BMI body mass index 
BMP8B  bone morphogenic protein 8B 
C/EBP  CCAAT enhancer binding protein 
cAMP cyclic adenosine monophosphate 
CCK cholecystokinin 
CL316,243  
disodium (R,R)-5-[2-[[2-(3-chlorophenyl)–2-hydroxyethyl]-
amino]-propyl]-1,3-benzodi-oxazole-2,2-dicarboxylate 
CMV  cytomegalovirus (promoter) 
CNS  central nervous system 
CREBP cAMP response-element binding protein 
CRH corticotropin-releasing hormone 
DMEM/F12 Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture F-12 Ham 
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DMH  dorsomedial nucleus (of the hypothalamus) 
EGFP enhanced green fluorescent protein 
FBS fetal bovine serum 
FCCP carbonyl cyanide-4-phenylhydrazone 
FFA free fatty acids 
FGF21  fibroblast growth factor 21 
FKPM fragments per kilobase million 
GDP guanosine diphosphate 
GPCR G-protein coupled receptor 
GTP guanosine triphosphate 
gWAT  gonadal white adipose tissue 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
HOXC9 homeobox c9 
HPA hypothalamic-pituitary-adrenal axis 
HSL hormone-sensitive lipase 
ICV intracerebroventricular 
IL-6  interleukin 6 
ingWAT  inguinal white adipose tissue 
IP3 inositol triphosphate 
MCP1  monocyte chemoattractant protein 1 
NPY  neuropeptide Y 
NR5A1 nuclear receptor subfamily 5 group A member 1 
PACAP pituitary adenylate cyclase-activating polypeptide 
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PKA protein kinase A 
PLC  phospholipase C 
PNS parasympathetic nervous system 
POMC  proopiomelanocortin 
PPAR- γ  peroxisome proliferator-activated receptor gamma 
PVH  paraventricular nucleus (of the hypothalamus) 
Rapgef4 Rap guanine nucleotide exchange factor 4 
ROI region of interest 
scAAV9 self-complimentary adeno-associated virus, serotype 9 
SF1 steroidogenic factor 1 
SNS sympathetic nervous system 
SVF stromal vascular fraction 
T2D type 2 diabetes 
TD-NMR Time-domain nuclear magnetic resonance 
TNFa  tumor necrosis factor alpha 
TRP transient receptor potential 
UCP1 uncoupling protein 1 
VEGFA  vascular endothelial growth factor A 
vg viral genomes 
VIP vasoactive intestinal peptide 
VMH ventromedial nucleus (of the hypothalamus) 
WAT  white adipose tissue 
β3-AR beta-3 adrenergic receptor 
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